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 ABSTRACT 
 
Discovery of disease-associated antibody biomarkers and their binding targets using 
bacterial displayed peptide libraries 
 
By  
 
Serra Eren Elliott 
 
Discovery of biologic molecules specific to a diseased state, or biomarkers, can 
lead to diagnostic development, therapeutic target identification, and improved 
understanding of disease pathogenesis.  Antibodies remain an attractive class of 
biomarkers given their amplification by the immune system, stability, and current 
clinical use.  While the antibody repertoire represents a rich source for biomarker 
discovery, it has been difficult to impartially identify which molecules from this 
repertoire are associated with disease.  This work demonstrates three molecular 
discovery processes centered on the utility of bacterial displayed peptide libraries and 
fluorescence activated cell sorting (FACS) for identifying novel antibody biomarkers 
and their targets.  We applied these methods to discover and characterize disease-
associated antibodies for pre-eclampsia (PE), a condition with unknown etiology that 
affects 5-8% of pregnancies, using an unbiased approach.   
Applying three quantitative screening strategies against a set of PE and healthy-
outcome pregnancies (HOP) identified unique disease-associated antibody binding 
peptides from a fully random 15 amino acid peptide library.  With a two-color 
screening method, we used antibody fractions enriched from plasma to isolate 
 viii
 significantly PE cross-reactive and specific peptides distinct from a previously 
identified PE-associated antibody specificity.  We used a panel of these antibody-
detecting peptides to train and validate an Adaptive Boosting classification algorithm 
that achieved high specificity (95%) and a validated overall 80% diagnostic accuracy.  
To more closely replicate the native antibody binding environment, a second 
screening method used unprocessed, diluted plasma.  This approach sequentially 
enriched peptides binding to PE antibodies and removed HOP antibody binders, 
resulting in a strong consensus motif that we further expanded through directed 
evolution.  Importantly, we linked this motif to a region of a common viral antigen, 
Epstein-Barr virus nuclear antigen 1, and a human G protein-coupled receptor, 
GPR50, presenting a novel case for molecular mimicry.  Thus, this method enabled 
unbiased identification of a disease-associated antibody and characterization of its 
targets.  Finally, we developed and applied a unique methodology that combines 
bacterial displayed library screening with next-generation sequencing to profile the 
antibody repertoire of individual PE patients and HOP samples.  This analysis re-
identified the viral antigen-linked motif among several distinct PE- and HOP-
associated antibody specificities, providing broader insights into alterations to the 
immune repertoire in PE.   
This work demonstrates the utility of screening bacterial displayed peptide 
libraries to profile the antibody repertoire and identify new markers of disease.  These 
disease-associated antibody-detecting peptide reagents enable development of 
molecular diagnostics and discovery of antibody binding target(s) to improve 
understanding of disease etiology and potentially elucidate therapeutic targets.   
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 1. Background 
 
The circulating human antibody repertoire catalogs the immune response to a 
variety of different targets, including pathogens, environmental allergens, and human 
proteins.  Determining and characterizing the targets of specific antibodies associated 
with a disease can lead to diagnostic development, improved understanding of disease 
pathogenesis, and elucidation of potential therapeutic targets.   However, it remains 
particularly difficult to unambiguously identify these disease-associated antibodies 
and their targets.  Through this research, we demonstrate methods that do not require 
sophisticated knowledge of disease pathogenesis to identify molecular diagnostic 
tools and elucidate antibody binding targets, which may enable future therapeutic 
development.  To emphasize the importance of an unbiased approach, we apply these 
methods to pre-eclampsia (PE), a disease with unknown etiology that affects 5-8% of 
pregnancies.1  While previous studies reported the presence of antibodies against a 
specific region of the angiotensin II type 1 receptor in PE patients,2,3 these have been 
difficult to detect and vary in prevalence. This chapter highlights the need for the 
development and application of unbiased antibody biomarker discovery tools, 
providing motivation for this work and describing the techniques involved.  
A.  Antibodies as disease-specific biomarkers 
In clinical proteomics, the proteins in diseased patients’ samples (i.e., blood, 
tissue) are compared with normal samples to determine biologic molecules unique to 
a diseased state, or biomarkers.4  Work in this area has been applied to a broad 
spectrum of diseases, such as cardiovascular disease,5 cancer,6 Alzheimer’s,7 and 
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 systemic lupus erythematosus,8 and has involved a variety of techniques, from mass 
spectroscopy9,10 and protein microarrays11 to gene transcription profiling.12  
In particular, the circulating antibody repertoire represents a rich source for 
biomarker discovery, due to easy access (blood sample), stability, and current clinical 
utility.  Antibodies, or immunoglobulins (Ig), can be divided into several different 
subtypes (IgG, IgM, IgA, IgE, IgD), of which IgG is the most prevalent (~75%) 
circulating class.  The Ig core structure consists of two heavy and two light chains 
comprising a constant fragment (Fc) linked to two regions responsible for binding 
(Fab), resulting in multivalency.  These multivalent antibodies bind to antigenic 
targets, which include proteins, carbohydrates, lipids, and nucleic acids.  The strength 
of the binding interaction between antibody (Ab) and antigen (Ag) is termed affinity, 
usually described by the equilibrium dissociation constant (KD):  
(1.1)     AgAb
ak
dk
AgAb ⋅+ ⎯⎯⎯⎯ →⎯ ⎯⎯⎯⎯ ⎯←    
(1.2)        
Ag][Ab
[Ab][Ag] ⋅== a
d
D k
kK  
 
The affinity of the antibody-antigen interaction plays a role in the ability to detect 
antibody markers.  A typical antibody affinity is 10-6 to 10-9 M, and this can be 
thought of as the concentration of antibody at which half of the antigen is bound.  
Thus, increased affinity (lower KD) results in a lower detection limit.  Specificity is 
another important consideration for a diagnostic assay.  Using an antigen that binds 
multiple nonspecific antibodies to detect a disease-associated antibody increases the 
number of falsely diagnosed healthy samples.   
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 Since antigenic targets are typically quite large, antibodies only recognize a small 
section of the antigen, termed an epitope.  Similarly, a small region, paratope, of the 
antibody composed of complementary determining regions mediates the majority of 
binding.  Epitopes can represent linear and discontinuous, conformational sections of 
a given antigen, or even complex macromolecular structures.13  Typical linear 
epitopes comprise 6 to 13 amino acids14 while conformational epitopes include 
stretches of linear regions typically resulting in 9 to 22 amino acids interacting with 
the antibody.15  These discontinuous epitopes are often difficult to precisely identify, 
resulting in large sections of proteins deemed important for antibody binding.16  
Additionally, certain protein structures, such as β-turns, are often observed in 
antigenic sites,17 further impressing the importance of structural context for antibody 
binding.   
Characterizing the precise epitope of interaction can clarify important differences 
associated with a specific disease.  For example, in celiac disease (CD), an immune 
response to gluten, a protein found in wheat, barley, and rye, leads to production of 
antibodies against the human protein, tissue transglutaminase (tTG).  Although rare, 
individuals with other autoimmune diseases demonstrate tTG antibody positivity in 
certain enzyme-linked immunosorbent assays (ELISAs).18  However, characterizing a 
discontinuous epitope for tTG antibodies in CD patients clarified differences between 
CD and these other disease patients with anti-tTG positivity.19   
Regardless of the precise mechanism of antigen interaction, many examples of 
antibody biomarker based diagnostics exist (Table 1-1).  Sensitivity and specificity 
are common metrics for assessing overall accuracy of a diagnostic assay.  In this 
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 respect, sensitivity represents the number of true positives (correctly diagnosed as 
disease) out of the total number of disease tested.  Conversely, specificity indicates 
the number of true negatives (correctly classified as healthy) out of the total number 
of healthy evaluated.   
B. Aberrant antibody production and molecular mimicry  
By interacting specifically with antigenic targets, antibodies perform a diverse set 
of functions and are necessary for healthy survival and protection against foreign 
molecules.  B-cells secrete antibodies upon binding of the appropriate antigen to the 
B-cell receptor and the necessary stimulation in a T-cell independent or dependent 
manner.20  Once appropriately stimulated, the B-cell undergoes an affinity maturation 
process, which fine-tunes the binding interaction by selecting for variants with 
increased affinity to the antigen after somatic hypermutation of the B-cell receptor 
binding region.  Focusing on the T-cell dependent process, antigens bound to the B-
cell receptor are internalized, digested, and displayed as fragments on MHC II, which 
must then interact with the appropriate T-cell receptor.  This two-step process helps 
regulate antibody production, reducing the likelihood of self-reactive antibodies.   
Despite this two-step process, various diseases are associated with production of 
unusual, often pathological antibodies, including chronic hypertension,21 
Alzheimer’s,22 chronic graft versus host disease23 and other autoimmune conditions.  
Therefore, sometimes a breakdown in self-reactive antibody production control can 
occur.  This breakdown could be due to aberrant epitope spreading as hypothesized 
for the generation of autoantibodies against tTG in CD.24  In this case, gliadin, a 
component of gluten, forms a complex with tTG as it acts upon the glutamine 
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 residues present. Thus, a tTG specific B-cell may endocytose the complex but present 
a gliadin peptide to a gliadin specific T-cell that stimulates the tTG specific B-cell to 
start producing antibodies.25  This epitope spreading phenomenon is associated with 
other diseases and has been shown to precede clinical presentation of rheumatoid 
arthritis.26 Furthermore, if the specific residues involved in the antibody-antigen 
binding are structurally similar to additional proteins, molecular mimicry between 
proteins can increase or trigger autoantibody production.27  For example, three 
autoantibodies associated with lupus patients have been shown to cross-react with 
regions of a common viral protein, Epstein-Barr virus nuclear antigen 1 (EBNA-1).28  
Molecular mimicry mechanisms have been proposed for several autoimmune diseases 
(Table 1-1): Guillain-Barré syndrome and Campylobacter jejuni;29 myasthenia gravis 
and herpes simplex virus 1;30 multiple sclerosis (MS) and Epstein-Barr virus (EBV), 
measles and HHV-6;30 type-1 diabetes (T1D) and Coxsackie B virus, rubella, and 
rhinovirus;30 and scleroderma and human cytomegalovirus.30  In certain cases, such as 
MS and T1D, the molecular mimicry mechanism is thought to involve cross-reactive 
T-cells.31   
As demonstrated by these examples, the molecular mimicry mechanism appears 
to play a significant role in generating autoimmune activity.  Discovering new 
molecular mimicry cases that drive autoantibody activity can improve our 
understanding of disease etiology and lead to new diagnostics and potentially 
therapeutics.  A variety of approaches have been used to discover and characterize 
disease-associated antibodies. 
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 Table 1-1: Examples of autoantibody markers of disease and hypothesized 
molecular mimicry in disease pathogenesis 
Disease Target Sens Spec 
Molecular 
Mimicry Proposed Refs 
Myasthenia 
 Gravis 
Acetylcholine receptor 0.96 0.97-
0.99 
Herpes simplex 1 
virus, gpD 
30,32, 
33 
Celiac disease Tissue transglutaminase 0.89a 0.98a Gluten, Hepatitis C 
virus 
30,34 
Type-1 diabetes Islet cells 0.81b
 
0.96b 
 
Enteroviruses, 
rotaviruses 
30,35,
36 
Systemic lupus 
erythematosus 
Nuclear antigens 
(ANA) 
0.98 0.92c 
0.88d 
Epstein-Barr virus, 
EBNA-1 
28,37 
 dsDNA 0.37 1c 
0.97d 
  
Systemic 
sclerosis 
Integrin-NAG-2 complex 
(endothelial cells) 
0.93e 1c,e Cytomegalovirus, 
UL94 
30,38,
39 
 Topoisomerase1  
(Scl-70) 
0.43c,f 1 c,f   
Graves’ disease Thyroid stimulating 
hormone receptor 
0.988 0.996c Yersinia 
enterocolitica 
40,41,
42 
Rheumatic fever Cardiac myosin 0.87 1d Streptococcal 43,44 
Autoimmune 
liver disease 
Cytochrome P4502D6 0.81 0.98 Hepatitis C virus, 
cytomegalovirus, 
herpes simplex 
virus 
45,46 
Rheumatoid 
arthritis 
Cyclic citrullinated 
peptide 
0.48 0.96 Proteus mirabilis 47,48 
 Fc domain of IgG (IgM-
Rheumatoid factor) 
0.54 0.91   
 
Sens – Sensitivity, Spec – Specificity, a – pooled estimate, b – median from review, c –
compared to healthy controls, d- compared to disease control patients, e – using a mimicking 
library-isolated peptide, f – measured by ELISA 
C.  Library screening to characterize disease-associated antibodies 
For the majority of diseases, a sensitive/specific antibody biomarker for diagnosis 
remains unidentified.  Furthermore, the push for more personalized medicine requires 
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 new discovery efforts to help typify different diseases or predict and monitor response 
to a specific therapeutic.49  These discovery efforts for new antibody biomarkers 
involve a diverse set of techniques.  While there has been some work to develop 
techniques to characterize unique complementary determining regions of antibodies 
using mass spectrometry,50 it remains difficult to apply and distinguish disease-
associated antibody markers.  More recently, with enhanced sequencing techniques, 
studies have been able to sequence the antibody repertoire itself and identify disease-
associated antibodies.51,52,53  However, in any effort to identify disease-specific 
antibody markers, it is important to characterize what the antibody binds.  Thus, a 
common technique is to screen a set of candidate antigen targets for binding to 
disease-associated antibodies.  
 
i. Protein microarrays 
Protein microarrays enable high-throughput evaluation of proteins of interest for 
binding to disease-associated antibodies in a multiplexed manner.54,55  Up to 103-104 
proteins are immobilized to a substrate, such as a glass slide, sometimes through 
affinity tags.56  By modifying substrate surfaces, proteins attach by noncovalent (e.g., 
hydrophobic or positively charged surfaces) or covalent (e.g., chemically activated 
surfaces such as epoxy or aldehyde esters) approaches.57 Alternatively, protein arrays 
can be generated using cDNA microarrays followed by in situ transcription and 
translation directly before probing for binding.11,58  While 103-104 proteins represents 
a fair amount of candidate targets, the human proteome alone may range from 105 to 
several million molecules, due to post-transcriptional control and post-translational 
modifications.57  This does not include the potential myriad of environmental 
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 organisms involved in disease.  Thus, selecting a set of proteins to evaluate with a 
microarray often requires pre-existing knowledge of the disease.  Utilizing these 
previously gained insights into disease etiology can lead to new discoveries, albeit in 
a specific direction.  For example, based upon the knowledge that lupus patients 
possess antibodies against certain “serum factors,” such as cytokines, chemokines, 
and growth hormones, a protein microarray was generated.59  Assaying this 
microarray for binding to serum antibodies in lupus patients and healthy controls 
identified B-cell activating factor (BAFF) as an autoantigen target among others for 
lupus-associated antibodies.   
In addition to the difficulty and bias introduced by selecting a set of proteins to 
analyze, generating the microarrays requires production, folding, and purification of 
these proteins, which adds significant complexity.  Given the solubility requirements 
for protein microarray analysis, membrane proteins, such as G protein-coupled 
receptors (GPCRs), must often be excluded from analysis.56   Some work has been 
done to print GPCRs and their associated lipids into microarrays using modified 
surfaces,60 but the requirement of detergents limits throughput.  Furthermore, with 
full-length protein microarrays, one cannot refine the important epitopes mediating 
the observed binding signal.   
ii. Peptide library screening 
Peptide library screening identifies short binding ligands for a variety of targets, 
such as disease-associated antibodies, out of a large pool of candidates. These 
peptides can be used as diagnostic reagents themselves and serve as antigen 
surrogates, enabling a more refined understanding of the epitope involved in an 
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 antibody-antigen interaction.  Although libraries of peptoids, synthetic peptide 
mimetics, have shown promise for disease detection,7,61 these are difficult to relate to 
the native antigen of interest.  Peptide libraries can be displayed on a cell surface or 
assayed as a solid-phase ELISA,17 microarray,62 or nitrocellulose membrane 
(SPOT).63  In one application, a peptide microarray consisting of 7,446 overlapping 
15 amino acid peptides representing 61 M. tuberculosis proteins was probed against 
tuberculosis positive and negative individuals.64  This analysis demonstrated that 
positive and negative individuals produced antibodies against different epitope 
specificities from the same protein while certain shared epitopes exhibited differential 
activity.  The SPOT synthesis methodology has been shown to map discontinuous 
epitopes of a known antigen; however, it requires high peptide density and protein 
concentration to identify these low affinity binders.65  By incorporating knowledge of 
the distance between discontinuous regions in a solved protein structure, these 
discontinuous regions were linked and substitution analysis led to improved binding 
affinity for the antibody.66  Although the SPOT and peptide microarray techniques 
can be useful, these approaches often require pre-existing knowledge of the antigen(s) 
of interest because peptide synthesis cost and efficiency limits the library diversity 
probed.  Since cell surface display uses the natural machinery of the cell to produce 
and display these libraries, the diversity probed can be significantly larger, 109-1011 
members.67  These libraries of peptides can be fully randomized or represent linear 
fragments of protein(s) of interest derived from the human proteome,68 a specific 
virus,14,69 or a particular cell line.70  Peptides identified from a randomized library 
may represent a linear sequence or mimic a discontinuous, conformational epitope 
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 (i.e., mimotopes71).  In fact, certain identified mimotopes can mimic the binding site 
of antibodies targeting double-stranded DNA.13  In contrast, libraries composed of 
linear overlapping fragments from a specific protein of interest typically cannot detect 
conformational epitopes.  The gene fragment library approach, which consists of 
different sized fragments from proteins of interest, can identify short linear epitopes 
and large sections of a protein that contain the residues of a discontinuous epitope.72  
In some cases, the known discontinuous regions can be used in conjunction to 
identify specific residues involved in binding.73  However, these approaches are more 
complex and require a priori knowledge of the disease to develop these fragment 
libraries in contrast to random peptide libraries.         
iii. Library screening by cell-surface display 
Peptide display libraries are a major tool for screening and identifying disease-
associated antibody binding peptides.  Commonly used display platforms include 
phage, bacteria, and yeast.  Phage, or bacteriophage, displayed libraries typically use 
M13 or T7 phage and have shown great utility for antibody repertoire profiling.  
Phage display screening against disease-associated antibodies has been applied to a 
variety of conditions, including infectious disease (e.g., Lyme disease74), 
inflammatory disease (e.g., ankylosing spondylitis75), and cancer (e.g., prostate,76,77 
breast,70 and non-small cell lung78), using random74-76 and cDNA libraries.70,77,78  
Furthermore, screening random phage display peptide libraries against autoimmune 
diseases has yielded interesting observations in multiple sclerosis,79 celiac disease,80 
and type-1 diabetes.81  In MS, four identified mimotopes bound antibodies in the 
cerebrospinal fluid in a higher fraction of MS patients compared to disease control, 
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 and these shared similarities with envelope proteins of the MS-associated retrovirus.79 
Screening IgA from CD patients with high anti-gliadin titers identified the PEQ 
sequence as important for binding to gliadin.80  Additionally, a monoclonal antibody 
from a T1D patient was screened against a randomized peptide library, which 
identified a common motif among isolated peptides.81  Similar cluster patterns were 
found on the surface of islet antigen 2 for which antibody specificities in type 1 
diabetes are hypothesized to be conformational.  However, in each case, prior 
knowledge of disease-related proteins, made these discoveries possible.  Additionally, 
phage cannot be quantitatively sorted because their small size (24-200 nm) prevents 
flow cytometric analysis.82  Instead, a simple selection process, termed panning, is 
used to enrich binding phage.  Here, antibodies are typically immobilized to a surface 
or beads and phage are panned for binding to the targets.  Furthermore, each panning 
step is followed by an amplification step hosted in bacteria, which greatly reduces 
library diversity independently from peptide function selection.83  
Bacterial displayed peptide libraries utilize the processing capabilities and fast 
replication of bacteria to display and screen a diverse collection of peptides for 
binding.  Bacteria provide a convenient, more easily accessible link between the gene 
and protein binding phenotype.  Moreover, bacterial display enables analysis by flow 
cytometry and fluorescence activated cell sorting (FACS) to quantitatively assess the 
degree of binding based on cell fluorescent intensities,84 discussed in detail later in 
this chapter.  Bacteria can also be selected in a similar fashion as phage display but 
without the biasing amplification process, such as with the flagellar display system, 
FliTrx.85  This system has been applied to identify antibody binding specificities 
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 present in scleroderma,38 Sjögren’s syndrome,86 Cogan’s syndrome,87 and 
autoimmune pancreatitis.88  Of these, the antibody binding specificity discovered for 
autoimmune pancreatitis exhibited the strongest diagnostic performance with binding 
activity observed in 18 of 20 patients and only 4 of 40 with pancreatic cancer.   The 
identified peptide sequence was linked to a protein of Helicobacter pylori, and the 
corresponding peptide exhibited similar diagnostic utility in a validation set.   
In addition to the FliTrx system, another bacterial display system of random 
peptide libraries utilizes FACS to identify peptides of interest.  The library displays 
using a circularly permuted version of the outer membrane protein X in E. coli,89 for 
which the display efficiency was further enhanced (eCPX).90  The scaffold enables 
peptide expression on both the N- and C-terminus, which provides more peptide 
flexibility than simple loop insertion into the native transmembrane protein.  This 
permits construction of a library of cells expressing unique peptides that behave more 
like in solution.  To demonstrate the capabilities of this display system, a 15-mer 
library was screened against a pseudo disease consisting of a monoclonal antibody 
spiked into an immunoglobulin pool.91  Multi-parameter cell sorting and differently 
labeled “disease” and control pools enabled selection of “disease” specific peptides, 
which were enhanced with directed evolution.    
While yeast display platforms can be screened by flow cytometry, these require 
longer growth times and due to poor transformation efficiency require multiple 
transformations to achieve >107 diversity.  A benefit to yeast display involves its 
ability to correctly fold and express larger proteins, such as fragments of epidermal 
growth factor receptor.92  Conformational and linear antibody epitopes were 
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 distinguished using these fragments.  Similarly, fragment display enabled refinement 
of the binding target for an H1N1 neutralizing antibody.93  These examples highlight 
the benefit of yeast display to express large structural domains from proteins of 
interest, but this approach again requires pre-existing knowledge of potential disease 
targets to characterize antibody binding. 
It is important to note that multiple copies (~10,000 with eCPX) of the peptide are 
expressed on the cell surface.  Therefore, binding interactions to multivalent 
antibodies not only depend on the individual affinity of the peptide for the target but 
also the avidity contributions based on the number of copies displayed on the cell 
surface. The peptides on the surface can be modeled as multivalent ligands and the 
avidity is determined by the inter- and intramolecular binding affinities.  The distance 
between two peptides depends upon the overall density of peptide expression on the 
cell surface.  With bivalent targets, such as IgG, if two peptides are displayed close to 
each other, two unbinding events must occur in rapid succession for the antibody to 
completely dissociate from the cell surface.  Thus, these avidity interactions enhance 
apparent affinities and, importantly, increase the ability to detect the presence of 
antibodies with low affinity or titer.94,95    
iv. Identifying antibody-detecting peptides from a bacterial display library 
With the tools described above, the disease-associated antibody-binding peptides 
can be selected from a random peptide library using a quantitative molecular 
separation process through flow cytometry (see Techniques section).  Importantly, as 
mentioned above, random peptide libraries do not necessitate prior knowledge of 
disease, unlike cDNA libraries generated from tissues or cells previously linked to 
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 disease.14,70,77,78  Some studies used few individual patient samples76,79 or a single 
pool of samples38,86-88 for discovery.  However, this approach biases antibody 
identification to a subset of patients, deterring identification of widely prevalent 
antibodies.  By incorporating FACS, peptides can be quantitatively screened for 
cross-reactivity among different patient samples.  These peptides represent antigen 
surrogates, which enables antigenic target characterization based upon sequence 
alignments of identified peptides.  Previous studies with random peptide libraries 
often relied upon few peptide sequences (<10) 38,79,81,86-88 and pre-existing knowledge 
of disease-related antigens74,79-81,86,88 to relate motif similarities to potential antigenic 
targets. However, greater sequence depth facilitates stronger motif characterization to 
understand the variability in certain positions, which would benefit a directed 
evolution strategy for unbiased antigen discovery.  Programs, such as PILEUP,96 
Clustal series,97 and MEME,98 are available to perform these sequence alignments.  
These tools relate amino acids using similarity matrices, such as the blocks 
substitution matrix (BLOSUM)99 and the Tudos matrix generated using the idea of 
“neighborhood selectivity.”100  Highly enriched populations of short (~15 amino 
acids) peptide sequences can often be aligned manually based upon these similarity 
matrices and amino acid properties.  Thus, bacterial displayed peptide library 
screening enables profiling of the immune repertoire to identify aberrant antibody 
specificities involved in a disease, potentially developed in response to an 
environmental trigger, such as a virus (Figure 1-1).  The following section describes 
the motivation behind applying this method to profile the immune response in the 
pregnancy-related disease, pre-eclampsia.   
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Figure 1-1: Bacterial displayed peptide library screening to profile the antibody repertoire. 
(A) An immunologic response to a particular pathogen, such as a virus, initiates production
of antibodies against specific proteins, or antigens.  These can result in binding to antigen
regions, or epitopes, typically observed or an atypical response.  When these atypical 
specificities cross-react with regions of human proteins, a process known as molecular
mimicry, these aberrant antibodies can lead to various problems.  (B) Since these linear 
epitopes are typically 6-13 amino acids in length a 15 amino acid peptide library can be used
to represent these important binding regions.  With fluorescently tagged antibodies, a
quantitative separation process, known as FACS, can be used to select the relevant disease-
associated specificities.   
D. Pre-eclampsia 
Pre-eclampsia (PE) affects 5-8% of pregnancies1 and is a major cause of maternal 
mortality (15-20% in developed countries) and morbidities.101  Furthermore, it is 
responsible for an estimated 500,000 fetal deaths worldwide each year.  PE is marked 
by placental abnormalities, such as poor placentation102,103 leading to intrauterine 
growth restriction (IUGR), as well as a maternal inflammatory response and 
endothelial dysfunction, which are involved with the mother’s clinical symptoms.103  
Established guidelines exist for diagnosing PE upon presentation with maternal 
symptoms, such as hypertension and proteinuria after 20 weeks’ gestation;104 
 15
 however, the disease pathogenesis remains poorly understood and presentation 
involves a broad clinical spectrum besides hypertension and proteinuria.105  It has 
recently been proposed that PE may represent a combination of several disease 
subtypes and future studies should recognize this possibility.106  Alongside the 
complicated nature of PE presentation and management, the average cost of a PE case 
is estimated to be £9000 ($14,000).107  Given the global impact of PE, a huge void 
remains to be filled with respect to advancing diagnostic methods, understanding 
disease pathogenesis, and developing an eventual therapeutic.   
i. Current understanding of disease 
Previous work has demonstrated that numerous contributing factors may lead to 
the maternal PE condition.  Several molecules, including cystatin C, beta-trace 
protein, and beta-2-microglobulin, increased in healthy pregnancy show further 
elevation in women with PE.108  Notably, disturbances to angiogenic/antiangiogenic 
protein levels have been observed in PE.  Elevated levels of antiangiogenic proteins, 
soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sEng), findings 
attributed to increased shedding of placental microparticles,109 and lowered levels of 
placental growth factor (PlGF) are often present in PE patients.110,111,112  sFlt-1 binds 
vascular endothelial growth factor (VEGF), thereby inhibiting VEGF’s normal 
proangiogenic activity.  The placenta-derived protein sEng induces vascular 
permeability and hypertension in vivo and is present in the sera of all pregnant women 
but elevated in PE patients.111  Although high sFlt-1 and low PlGF levels have been 
demonstrated in a large number of patients, not all women with these altered levels 
develop PE and many PE patients present without these differences,113,114 indicating 
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 the existence of other factors that contribute to PE.  One factor contributing to the 
altered renin-angiotensin system may come from oxidative stress due to placental 
dysfunction.  A study showed renin more readily cleaved the oxidized form of 
angiotensinogen to form angiotensin, which angiotensin converting enzyme (ACE) 
eventually converts to angiotensin II.115  Furthermore, the ratio of reduced to oxidized 
angiotensinogen was lowered in a small group of PE patients.  Another effect of 
placental dysfunction in PE involves decreased levels of catechol-o-methyltransferase 
(COMT) leading to lower levels of the hypoxia-inducible factor-1α inhibitor protein 
2-methoxyoestradiol (2-ME), normally elevated during pregnancy.116  
Besides the alterations of these various proteins already affected in normal 
pregnancies, evidence suggests an immunological response associated with PE.  
Alterations in inflammatory cytokines, such as increased levels of pro-inflammatory 
TNFα, IL-6, and IL-8 have been observed in women with PE.117  In addition, the 
complement system, potently activated by antibody binding, appears dysregulated in 
PE,118,119 since levels of several complement proteins are increased in PE.119,120,121  
Mutations in complement regulatory proteins have been associated with an increased 
risk for PE.118  While PE placental tissue showed increased presence of complement 
protein C4d, this was associated with higher levels of mRNA for complement 
regulatory proteins.119  Furthermore, placental vessels in a transgenic rat model of PE 
showed increased C3 deposits, and supernatant from PE placental explants stimulates 
C3 expression in rat vascular smooth muscle cells.122  In addition to increased 
complement, patients with PE exhibit decreased circulating123 and placental124 levels 
of CD4+CD25+FoxP3+ regulatory T-cells.  These regulatory T-cells help control self-
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 reactive antibody production; thus, this reduction can lead to increased autoantibody 
production.125  Furthermore, PE patients possess expanded levels of circulating 
CD19+CD5+ B-cells,126 which produce natural antibodies and are similarly increased 
in autoimmune diseases, including Sjögren’s syndrome and rheumatoid arthritis.127  
Taken together, these observations provide evidence for an immunological response 
consistent with aberrant antibody production in PE.   
Several studies implicate autoantibody binding activity in patients with PE.  PE-
associated antibodies have been shown to bind human proteins, such as β1, β2 and α1 
adrenoreceptors,128 cardiolipin,129 and prothrombin.130  Most notably, PE patients 
produce agonistic autoantibodies against the angiotensin II AT1 receptor (AT1-AA)2 
that can induce PE symptoms, such as hypertension, proteinuria, and raised sFlt-1 
levels, in pregnant mice.3  Other studies have further demonstrated these antibodies 
precede and induce sFlt-1131,132 and sEng production.132  It was later shown that the 
AT1-AA crosses the placenta and contributes to the IUGR often observed in PE.133  
Through competition experiments, scientists identified a seven amino acid epitope 
(AFHYESQ) on the second extracellular loop of the AT1 receptor using antibodies 
isolated from PE patients2 as well as a transgenic rat model.134  This epitope was 
noted to resemble a section on the parvovirus B19 capsid protein VP2 and a human 
antibody against this protein demonstrated activity in the bioassay used to determine 
the presence of AT1-AA, suggesting molecular mimicry as a source for generating 
these AT1-AAs.135  Importantly, co-injection into pregnant mice of the epitope and 
the antibodies isolated from PE patients prevented the manifestation of clinical 
symptoms.3  Although AT1-AAs are found as early as 18 weeks’ gestation, one 
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 deterrent to utility as a biomarker for PE is the presence of these antibodies in sera of 
women with abnormal placental perfusion but no PE.136  Addressing the specificity of 
AT1-AAs and resolving whether they are present in all PE cases has been hindered 
because the low antibody titer or affinity impedes ELISA analysis, forcing 
dependence on complex bioassays to determine the presence of AT1-AAs.137,138  
Further investigation of the AT1-AA’s presence in normal pregnancies and PE 
patients will benefit from a method to increase affinity through avidity effects,94,95 
such as bacteria displaying multiple copies of the epitope.  Additionally, attempts to 
isolate other autoantibody biomarkers that may be more specific than the AT1-AA are 
required to advance this hypothesis of an abnormal immune response in PE.    
ii. Necessity of a novel diagnostic assay  
Current diagnosis of PE relies upon presentation of maternal clinical symptoms, 
including hypertension and proteinuria.104  However, 10-15% of pregnant women 
who progress to hemolysis, elevated liver enzymes, and low platelet count (HELLP) 
syndrome and 20-25% of those that develop eclampsia never present with 
hypertension or proteinuria.139  Various groups have suggested using the altered 
levels of sFlt-1, PlGF and sEng as predictors for pre-eclampsia.  Elevated levels of 
sFlt-1 can occur five weeks before clinical manifestations, and decreased levels of 
PlGF can be observed as early as the first trimester of those that develop PE.140  
Several small studies have shown the diagnostic/predictive abilities of these 
angiogenic factors,141 and recently diagnostic aids were constructed to detect levels of 
sFlt-1 and PlGF in patient samples.  Studies on these assays demonstrated that the 
ratio of the proteins may be helpful for diagnosis.142,143  However the PE sample sizes 
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 in these two studies were small (15 and 48, respectively) and other studies have 
shown great variability in the sensitivity (62-100%) and specificity (51-85%) of the 
sFlt-1/PlGF ratio.105  As can be expected due to the normal increase in sFlt-1 
concentration during the third trimester, the assay performs better for diagnosing 
early-onset PE105 (before 34 weeks), which only occurs in 10% of PE cases.1  
Additionally, one study evaluating alterations of sFlt-1, PlGF, and sEng in PE 
patients with high risk pregnancies, such as diabetes and chronic hypertension, 
demonstrated only modest differences and odds ratios close to or below one.144 
Ideally, one would be able to predict future PE presentation early on during the 
first or second trimester.  Several studies have evaluated certain clinical risk factors 
(e.g., family history, obesity, smoking, etc.).145  However, one recent study evaluated 
47 different biomarkers alongside various risk factors for predictive performance at 
14-16 weeks’ gestation.146  Most of these markers showed only modest differences 
between PE and healthy controls in a large cohort (n=5623).  Constructing and 
evaluating diagnostic algorithms revealed that only PlGF and cystatin C protein levels 
enhanced predictive performance over clinical characteristics alone for early-onset 
PE.  Thus, while prediction may be ideal, this may be difficult to achieve due to 
disease complexity.  However, enhanced understanding of disease-associated 
molecules is essential for any future predictive diagnostic and potentially eventual 
therapeutic development.  
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 E.  Techniques  
i. Flow cytometry and fluorescence activated cell sorting 
Through flow cytometry, cells are forced into a single-file line to be interrogated 
by a laser(s).  Following interrogation by a blue laser (488 nm), the side scatter 
(SSC), which measures refracted or reflected light 90° from the laser line, and 
forward scatter (FSC), diffracted light, are used to characterize the relative 
complexity and size, respectively, of the cell population.  By gating the appropriate 
population, the analysis focuses on healthy and singlet cells, instead of cell 
aggregates.  A variety of additional fluorescent parameters can be measured 
simultaneously using the blue laser or others, such as a red laser (633 nm).  Thus, a 
given cell population can be incubated with multiple fluorescently tagged reagents 
(e.g., antibodies) and quantitatively assessed for the presence of these tags.  
Importantly, based on the degree of fluorescence, an individual cell, for our purposes 
bacteria, can be collected or discarded (Figure 1-2) in a process known as 
fluorescence activated cell sorting (FACS).  In this case, a gate is created to eliminate 
low or non-fluorescent cells based upon the background fluorescence of a negative 
control.  The binding reagents of interest can either be directly conjugated to a tag, or 
a fluorophore-conjugated secondary reagent may be used to bind specifically to the 
protein of interest amongst an assortment of irrelevant proteins.  Commonly used 
fluorophores include the Invitrogen Alexa series, such as Alexa488, and R-
phycoerythrin.  Both Alexa488 and R-phycoerythrin excite at 488 nm; however, their 
spectra differ, enabling distinct emission detection with 530 nm and 576 nm 
photomultiplier tubes, respectively.    
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Figure 1-2: Schematic of fluorescence activated cell sorting (FACS) with a bacterial-
displayed peptide library.   
ii. Bacterial displayed library design 
Traditional libraries are often linear, fully randomized amino acid sequences at a 
user-specified length.  Although the length of a typical linear region of a protein that 
interacts with an antibody, or epitope, is 6-13 amino acids long,14 a longer peptide of 
15 amino acids on the surface may provide structural context with the flanking amino 
acids.  Building upon this idea of conformational significance and taking influence 
from the highly selective conotoxin proteins in cone snail venom,147,148 a multiply-
constrained (MC) library was constructed with a network of four cysteines, which 
form disulfide bonds that impart structural constraints.  Since protein structure is a 
significant aspect of binding, the MC library may yield ligands with high affinity and 
specificity for disease-associated antibodies.   
 To test this hypothesis, we screened traditional libraries (linear and singly-
constrained) and the MC library against a model therapeutic antibody, Herceptin.  
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 Utilizing stringent conditions (low nanomolar concentrations) ensured selection of 
high affinity binding ligands.  The isolated sequences and a previously identified 
linear mimotope (H98)149 cloned for bacterial surface expression were compared for 
apparent affinity (Table 1-2).  Analysis by flow cytometry determined fluorescent 
signals associated with peptide binding at varied concentrations of the target antibody 
([T]).  After subtracting the background (Flbkgd) from the mean cell fluorescence 
(MCF), the data was fit to Equation 1.3, derived from Equation 1.2 above.  This 
analysis established the maximum fluorescence (Flmax) and apparent affinity (KD,app) 
for each displayed peptide.  
    (1.3) 
Table 1-2: Properties of Herceptin binding peptides 
 
Clone 
 
Sequence 
KD, App 
 (nM) 
 
Flmax 
Percent 
 Deviation 
MC-1   GCCLYGTCDLDSCG 4 5,800 24.2 
MC-2 GCHSNCAFSCELDCG 5 18,000 6.3 
MC-3   GCCDKNTCDLDHCTCG 24 15,300 12.7 
MC-4 GCFQSGCSEGSSGCTRQWCG 27 9,950 13.2 
Trad-1  RFP-TQVDTNRICCFVM 17 8,400 14.9 
Trad-2 GIFACGQVWSESCGSKE 142 21,000 17.7 
H98 LLGPYELWELSH [149] 9 23,500 11.6 
 
To evaluate the peptides’ apparent affinities, Flmax must be considered because 
this relates to the number of peptides on the cell surface and thus, the contribution of 
avidity effects to enhance apparent affinity.  Therefore, a low Flmax and KD,app 
represents the best overall apparent affinity.  MC-2 performed marginally better than 
the H98 peptide, and MC-1 exhibited the lowest Flmax and KD,app (Figure 1-3A), 
providing preliminary evidence that the MC library yields higher affinity peptides 
than traditional libraries.  Normalizing the fitted curves by the maximum fluorescence 
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 highlighted the similar apparent affinities observed for different peptides, such as 
MC-1 and MC-2, and the weaker affinity for the Trad-2 peptide (Figure 1-3B).  
Additional off-rate analysis might provide further insights into the binding kinetics of 
the different peptides.   
0
5000
10000
15000
20000
25000
0.01 0.1 1 10 100 1000
Herceptin Concentration (nM)
Fl
uo
re
sc
en
ce
 In
te
ns
ity
 
MC-1
MC-2
MC-3
MC-4
Trad1
Trad2
H98
0.01 0.1 1 10 100 1000
0.00
0.25
0.50
0.75
1.00
H98
MC-1
MC-2
MC-3
MC-4
Trad 1
Trad 2
Herceptin Concentration (nM)
N
or
m
al
iz
ed
 B
in
di
ng
 S
ig
na
l
A.
B.
 
 
Figure 1-3: Apparent affinity analysis of Herceptin binding clones.  (A) Experimental data 
(points) paired with fitted curves shows variability of maximum fluorescence and apparent
affinity. (B) Normalized fitted curves highlight similarities and differences in apparent affinity.   
  While identifying high affinity disease-associated antibody binders could benefit 
diagnostic development, we also sought to identify specific antibody binding peptide 
epitopes.  Library-designed cysteines could confound protein database searches using 
the generated motifs or possibly result in high affinity mimotopes that show no 
primary sequence resemblance to the original antigen.  For example, although the 
motif highlighted among three of the MC peptides (Table 1-2) resembles one of the 
three known regions (PEADQ) of interaction between Herceptin and HER2,150 the 
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 upstream cysteine in the peptide motif is a proline in the native sequence.  Thus, 
although the motif bears resemblance, this dissimilarity might result in a reduced 
score for a hit in database searches when the native antigen recognition sequences 
have not been determined.  Therefore, we selected a traditional, fully randomized 
linear library for use in disease-associated antibody specificity profiling.        
iii. Sequencing isolated peptides 
To identify the sequences corresponding to isolated peptides, the vector encoding 
the peptides must be sequenced and the region of interest identified.  Traditionally 
this proceeds by Sanger sequencing, which incorporates chain-terminating 
polymerase inhibitors.151  These can be attached to a dye and evaluated to effectively 
piece together the sequence of oligonucleotide residues.  Importing the obtained 
sequence files to analysis software, Geneious, enables easy translation of DNA to the 
amino acid sequences encoded.  By selecting individual colonies of bacteria isolated 
from screening, each peptide sequence is matched directly to the clone that encodes 
it. Therefore, following motif analysis, the individual peptides of interest can be 
easily studied further.  However, this process remains relatively low throughput, 
typically yielding only ~100s of sequences.   
In comparison, massively parallelized sequencing processes, next-generation 
sequencing (NGS), permit high-throughput analysis.  Several different instruments 
now exist with varied data output.  For example, the 454 sequencer yields 200,000 
reads of 250 bases, while tens of millions of shorter reads (35-50 bases) can be 
obtained on Illumina’s Genome Analyzer.152  Since these NGS methods return short 
sequence reads, the region of interest corresponding to the peptide sequence must first 
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 be amplified from a large library pool of vectors obtained from multiple bacterial 
clones each expressing a unique peptide.  Certain adapter regions are often added for 
the DNA to be sequenced on a specific instrument.  Applying a specific barcode to 
distinct samples enables pooling, thereby increasing throughput.  Although this 
results in a larger depth of sequencing, the specific clones displaying these peptides 
are not directly matched to the sequence.  Thus, sequences of interest must be 
reconstructed for expression.   
iv. Sample handling for diagnostic discovery 
Consented individuals provided samples of blood plasma for use in this work.  In 
the case of whole blood samples in EDTA, which prevents coagulation, the blood was 
centrifuged at 1000g and the plasma fraction isolated and aliquoted (50-200 μL) for 
storage at -20 or -80°C.  In other cases, collaborators provided plasma, which was 
then aliquoted and stored.  To prepare for diagnostic discovery, samples were either 
enriched for the antibody fractions, using ammonium sulfate precipitation reactions2 
or diluted 1:50.  In both cases, samples were depleted of E. coli binding antibodies.91  
Using antibody enriched fractions enabled direct conjugation of a labeling reagent, 
while the diluted plasma samples were labeled using an immunoglobulin G (IgG) 
specific secondary reagent.  While the directly labeled antibody enriched fractions 
facilitated multi-parameter cell sorting, the diluted plasma more closely replicates the 
binding conditions in the body and is anticipated to better support future diagnostic 
development.    
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 v. Peptide reactivity analysis 
Bacterial library screening typically reduced library diversity from 8x109 
members to ~1000 peptides.  From these unique peptides, we must identify the one(s) 
showing the highest sensitivity and specificity.  To characterize peptide reactivity 
with patient antibodies, an individual bacterial clone is incubated with several 
different PE and HOP antibody samples followed by fluorescent labeling of these 
cell-bound antibodies and FACS analysis.  This FACS-based analysis recaptures the 
environment used in screening; however, it lacks throughput.  Previous work in the 
lab identified that high density (1011 cells/mL) printing of cells could be probed by a 
monoclonal antibody.153   Thus, to increase throughput, we investigated the utility of 
a bacterial microarray for analyzing antibody fractions from human patients.  After 
printing, the array was heat treated at 65°C for 45 minutes before proceeding to a two 
hour blocking step with 5% milk and 1.5% bovine serum albumin buffer.  A 
secondary labeling step with an antibody binding reagent, Protein A conjugated to 
Alexa647, followed incubation with 1 μM of unlabeled antibodies from ten PE and 
two HOP samples.  In comparing the heat map data obtained for the peptides through 
FACS (Figure 1-4A) and microarray analysis (Figure 1-4B), the results only weakly 
correlated qualitatively, and further analysis demonstrated this discrepancy to be true.  
Therefore, we concluded that while the bacterial microarray would enable higher-
throughput analysis, this could not accurately replace FACS based peptide reactivity 
analysis.  
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Figure 1-4: Different results observed for FACS and microarray-based peptide reactivity
analysis.  Peptides were analyzed for antibody binding activity to PE and HOP samples on
the (A) FACS and using a (B) bacterial microarray. 
vi. Developing diagnostic assays  
A diagnostic assay must achieve high accuracy (sensitivity and specificity) in 
distinguishing healthy from disease samples.  To optimize the performance of any 
diagnostic assay, varied activity cutoffs are plotted for sensitivity and specificity, in a 
receiver operating characteristic curve (ROC).  The area underneath this curve (AUC) 
is an additional metric indicating the overall performance of the assay, where 0.5 
indicates random chance and 1 represents a perfect diagnostic.   
In some cases, one to two antigens or antibody-detecting peptides representing a 
disease-associated antigen can achieve the sensitivity and specificity to serve as stand 
alone diagnostic tests.  Alternatively, an array of multiple reagents may be required to 
account for the variance in immune responses among patients that can lead to 
antibodies with differing epitope specificities, as seen in systemic lupus 
erythematous, where more than 150 putative autoantigens have been documented,13 
and myasthenia gravis.154  A phage-displayed peptide microarray strategy has been 
 developed for diagnosing prostate77 and breast cancer,78 achieving 88% and 84% 
specificity in a validation set, respectively. Configuring the peptide array in a manner 
that achieves a high surface area to volume ratio, such as with bacterial display, 
increases sensitivity of detection as demonstrated with polyvalent nanoparticles.155     
When a diagnostic assay is composed of multiple reagents and properties, a robust 
algorithm must be developed to combine these properties, optimizing for diagnostic 
accuracy.  In particular, various machine learning algorithms, which modify 
parameters based upon data provided, have been developed and implemented for 
constructing accurate classification algorithms for disease diagnosis.156  These 
algorithms are constructed, or trained, on a set of observed data from clinical samples.  
During the training, sampling methods, such as cross-validation and bootstrapping,157 
facilitate accuracy estimation and parameter optimization.  Cross-validation divides 
the training set into different groups, and trains the algorithm on all but one group (or 
single sample), which is used to test performance, and repeats for all groups.  Single-
sample testing, known as leave-one-out cross-validation, often overestimates the true 
accuracy, while another common method using ten approximately equal-sized groups, 
ten-fold cross-validation, can pessimistically underestimate the true accuracy.157  The 
support vector machine (SVM) algorithm, which maps data to a high-dimensional 
space that enables a linear separation of classes,158 remains a common choice for 
classifier development and has been used in a variety of studies.159,160  Another 
algorithm known as Adaptive Boosting, or AdaBoost, applies additive regression on 
reweighted versions of the training set to focus on misclassified samples after each 
round.161  AdaBoost has been shown to outperform SVM162 and is less prone to over-
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 fit the training data than other algorithms.163  Additionally, if over-fitting becomes 
apparent, methods exist to overcome this problem.163   
vii. Identifying antigenic targets 
A consensus region represents the important residues mediating the mimicked 
antibody-antigen interaction.  Therefore, a protein database search for 
similar/identical sequences to peptide motif(s) using NCBI BLASTp164 and/or 
ExPasy ScanProsite165 identifies candidate antigens. These searches can be limited to 
the human proteome to identify potential autoantigens, a specific organism known to 
be involved in disease, or left broad to identify all possible hits.  A broad search 
enables identification of potential trigger antigens, which may have led to cases of 
molecular mimicry for aberrant autoantibody binding.  Conformational epitopes 
resulting from random peptide libraries complicate the discovery of potential 
antigenic targets, since the native protein would have long stretches separating the 
amino acids closely linked together in the mimotope.  Since conformational epitopes 
make up a significant portion (possibly as high as 90%) of antibody specificities,166 
certain algorithms exist to assist with their prediction.166  Additionally, one algorithm 
in particular, incorporates peptide sequences generated by library screening for 
alignment with discontinuous portions of the antigen.167  However, this only works 
for known target proteins with characterized structures.  Thus, the main focus of this 
system of identifying antigenic targets through random peptide library screening 
focuses on linear epitope identification or linear sections composing a larger 
discontinuous epitope. 
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 2. Characterization of antibody specificities associated with pre-eclampsia  
  
The presence of maternal autoantibodies has been previously associated with pre-
eclampsia, although the composition of the antibody repertoire in pre-eclampsia has 
not been well characterized.  Given this, we applied a bacterial display peptide library 
to identify peptides that preferentially react with plasma antibodies from patients with 
pre-eclampsia (n=15) versus healthy-outcome pregnancies (n=18). Screening using 
fluorescence-activated cell sorting identified 38 peptides that preferentially bind to 
antibodies from individuals with pre-eclampsia. These pre-eclampsia-specific 
peptides possessed similar motifs of RG/SG/-WWG/S, RWWG/S, or WGWGXXR/K 
distinct from the angiotensin II type 1 receptor epitope AFHYESQ.  Seven library-
isolated peptides and a cell surface-displayed angiotensin II type 1 receptor epitope 
were used to construct a diagnostic algorithm with a training set of 18 new pre-
eclamptic and 22 healthy-outcome samples from geographically distinct cohorts. 
Cross-validation within the training group resulted in averaged areas underneath a 
receiver operating characteristic curve of 0.78 and 0.72 with and without the known 
receptor epitope, respectively.  In a small validation set (12 pre-eclamptic; 8 healthy), 
the algorithm consisting only of library-isolated peptides correctly classified 10 pre-
eclamptic and 6 healthy, using a predefined cutoff that achieved 61% sensitivity 
(95% confidence interval, 36-83%) at 95% specificity (95% confidence interval, 77-
100%) in training set (n=40) cross-validation.  Our results indicate that antibodies 
with specificities other than anti-angiotensin II type 1 receptor are prevalent in pre-
eclampsia patients and may be useful as diagnostic biomarkers. 
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 A. Introduction 
Pre-eclampsia (PE) is a serious disorder that affects 5% to 8% of pregnancies1 
and causes 15% to 20% of maternal mortalities and morbidities in developed 
countries.101 Despite serious global effect, the primary method of PE diagnosis 
continues to rely on presentation of maternal symptoms, including hypertension and 
proteinuria, after 20 weeks of gestation.  However, present diagnostic approaches are 
inadequate to identify patients likely to experience adverse outcomes since 10% to 
15% of women who experience hemolysis, elevated liver enzymes, and low platelet 
levels (HELLP syndrome) and 20% to 25% who progress to eclampsia do not present 
with either hypertension or proteinuria.139 Consequently, there remains a need for 
noninvasive diagnostics that can accurately and reliably identify patients who develop 
PE and those at risk for adverse outcomes. 
Diagnostic development efforts have focused on the identification of protein 
biomarkers with unique presentation in PE.  Multiple proteins exhibit altered serum 
levels in PE and have been pursued as candidate biomarkers and therapeutic targets, 
including soluble vascular endothelial growth factor receptor (sFlt-1), placental 
growth factor (PlGF),113 soluble endoglin,111 placental protein 13,168 and angiotensin 
II type 1 receptor (AT1) autoantibodies (AT1-AAs).2  In particular, much effort has 
focused on evaluating the diagnostic utility of the ratio of the elevated sFlt-1 to 
lowered PlGF levels or the PlGF level alone.169  These biomarkers have yielded high 
diagnostic accuracy for detecting early-onset PE and predicting adverse outcomes.170  
However, these biomarkers are less effective after 34 weeks’ gestation,169 the period 
where 90% of PE cases present.1   Finally, they do not enable accurate prediction of 
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 PE during the first trimester,171 since sFlt-1 levels only become significantly altered 
≈5 weeks before PE onset.112 Therefore, despite the use of these biomarkers for early-
onset PE detection, additional biomarkers are needed. 
Circulating antibodies represent a rich source for additional biomarker discovery, 
and several observations link the immune system to PE pathogenesis.  Most 
prominently, patients with PE have been found to produce agonistic immunoglobulin 
(Ig) AT1-AAs2 as early as 18 weeks’ gestation.136  Several in vivo and in vitro studies 
have demonstrated a potential pathological role for these antibodies.  Injection of 
AT1-AAs or total IgG isolated from PE patients into pregnant mice induced the 
hallmark PE symptoms (hypertension, proteinuria, and increased sFlt-13 and fetal 
growth restriction133), whereas coinjection with an antibody-blocking peptide epitope 
attenuated these effects.  Interestingly, placental ischemia-stimulated AT1-AAs 
similarly contribute to hypertension in an independent PE rat model.172  AT1-AAs 
increase complement protein C3 deposition in the placenta and kidney of pregnant 
mice,173 while mutations within complement system regulatory proteins seem to be a 
risk factor for PE.118 Complement activation has been further implicated in PE with 
increased C3 deposits in placental vessels from a transgenic PE rat model, and 
supernatant from PE placental explants stimulate C3 expression in rat vascular 
smooth muscle cells.122  Furthermore, isolated CD19+CD5+ B-cells are elevated in PE 
and produce AT1-AAs in culture upon addition of PE serum.126  At the same time, 
individuals with PE exhibit significantly reduced levels of CD4+CD25+ regulatory T-
cells,123 a finding consistent with increased autoantibody production.125 Collectively, 
 33
 these previous studies indicate that immunological alterations are a conserved feature 
in PE.  
Despite a demonstrated role of AT1-AAs in the pathology of PE, their efficacy for 
PE diagnosis has not been established.  Existing assays for AT1-AAs that rely on 
cardiomyocyte beat rate2 or a luciferase reporter138 lack throughput and are unsuitable 
for point-of-care diagnostics.  More importantly, AT1-AA prevalence varies 
significantly in different studies (70%135-95%138), and AT1-AAs are not specific to 
PE because they have been observed in individuals with healthy-outcome pregnancy 
(HOP),135 chronic hypertension,21 and renal allograft rejection.174  Given these 
problems, we investigated whether additional PE-specific antibodies exist that could 
serve as biomarker(s) for PE diagnosis and further implicate a pathophysiological 
role for an altered immune system.  To simultaneously identify antibody biomarkers 
and peptide reagents for their detection, we screened a bacterial display peptide 
library91 against antibodies enriched from the plasma of individuals with PE and 
HOPs. Our results demonstrate the existence of PE-specific plasma antibodies, other 
than AT1-AAs, that may be useful for PE diagnosis.   
B. Materials and Methods  
i. Patient Samples 
Whole blood samples were obtained from pregnant women as aliquots of samples 
taken for routine blood work during clinical assessments at the Santa Barbara Cottage 
Hospital (cohort 1).  The study was approved by the Santa Barbara Cottage Hospital 
review board.  To qualify as affected with PE, subjects fulfilled ≥2 of the following 
criteria: (1) 2 documented blood pressures (BPs) with readings >140/90mm Hg ≥4 
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 hours apart, with documented normal BPs in the first half of the pregnancy; (2) 
proteinuria as defined by ≥30 mg/dL on a spot urine check, ≥1+ dipstick reading, or 
≥300 mg/24 hr; (3) central nervous system (CNS) symptoms (visual disturbances or 
unremitting headaches); (4) epigastric pain associated with elevated liver enzymes 
unrelated to other abdominal pathology; or (5) thrombocytopenia with platelet counts 
<100000 U/mL.  This ensured that PE samples met the American College for 
Obstetricians and Gynecologists criteria for mild or severe PE diagnosis. Pre-existing 
hypertension and lupus patients were excluded from cohort 1.  Samples were divided 
into a discovery set (n=33) for initial peptide identification and a training set (n=20) 
for testing diagnostic ability of isolated peptides.  Additional deidentified samples 
provided from University of Texas Medical School at Houston (cohort 2) were used 
in either the training set (n=20) or a validation set (n=20).  These PE samples were 
diagnosed by clinical assessments based on the National High Blood Pressure 
Education Program Working Group Report.  
This study did not distinguish between early- and late-onset PE and did not 
discriminate based on parity. Therefore, these cohorts represent a mix of presentation 
times and parities.  All subjects provided informed consent, and samples were 
collected according to institutional guidelines.  Blood samples for both cohorts were 
obtained near the time of delivery.  In cohort 1, BPs were recorded at the time of 
presentation whereas cohort 2 recorded maximum BP before delivery.  In addition, 
while cohort 1 mainly used the spot urine check, cohort 2 diagnosis used 24-hour 
analysis and the dipstick test (n=7).   
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 ii. Bacterial display and library screening 
 The AT1 epitope AFHYESQ was displayed on Escherichia coli MC1061175 
with flanking glycines as a fusion to the N-terminus of the eCPX (enhanced circularly 
permuted OmpX) scaffold90 along with a C-terminal peptide tag (P2x) that binds a 
fluorescent reporter (YPet-Mona) of scaffold expression.176  A 15-mer random 
peptide library displayed on the N terminus of the eCPX scaffold was screened for 
peptides binding to PE-specific antibodies.  All cultures for screening and analysis 
were subcultured (1:50), grown to an OD600 of 0.4-0.6, and induced for one hour with 
0.04% arabinose.  Library screening used antibody fractions in PBS (0.1% BSA) 
prepared by ammonium sulfate precipitation of patient plasma and depleted of E. coli 
binding antibodies.  Magnetic selection enriched for peptides that bind pooled PE 
(n=9) antibodies (5 μmol/L total concentration) labeled with the FluoReporter Mini-
Biotin-XX Protein Labeling Kit (Invitrogen) while outcompeting an unlabeled pool 
of HOP (n=12) antibodies (5 μmol/L total).  Streptavidin (SA) binding peptides were 
removed from the library using MyOne SA-coated magnetic beads. To favor cross-
reactivity, 2 pools of PE antibodies with distinct fluorophores were prepared: group 1 
(n=4) labeled with Alexa Fluor 488 (Invitrogen; green) and group 2 (n=5) 
biotinylated (red) to enable detection with streptavidin-conjugated R-phycoerythrin 
(Invitrogen).  Cells were coincubated with excess unlabeled HOP antibodies and 
labeled PE antibodies, and those cells exhibiting both red and green fluorescence 
were recovered by fluorescence-activated cell sorting (FACS) (Figure 2-1A).  The 
first FACS round utilized 2.5 μmol/L from each PE group and five-fold excess HOP 
pool, while the subsequent two rounds lowered the PE concentration to 1 μmol/L and 
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 increased normal antibodies to 10 and 15-fold excess, respectively.  Peptides with 
specificity for PE antibodies were favored in separate sorts using a PE antibody pool 
(n=9) labeled with Alexa Fluor 488 and a biotinylated HOP antibody (n=12) pool.  
After recovering nonfluorescent cells that did not capture HOP antibodies (1 μmol/L), 
cells exhibiting green, not red, fluorescence were collected after labeling with PE and 
HOP antibody pools (1 μmol/L, each) followed by streptavidin-conjugated R-
phycoerythrin (Figure 2-1B).  Screening continued with a set of new PE and HOP 
(n=6 each) samples to enhance PE cross-reactivity and specificity.  After completing 
rounds six and seven for cross-reactivity sorting with 1 μmol/L of each disease group 
and unlabeled 15-fold excess and 20-fold excess of HOP, respectively, two 
specificity rounds were performed to select peptides binding only disease samples as 
described above.  Another negative sorting round enriched bacteria displaying 
peptides that did not bind the biotinylated HOP antibody pool.  Finally, three 
additional rounds of peptide enrichment were performed towards binding pooled PE 
(1 μmol/L) but not HOP (2.5 or 1 μmol/L) antibodies, using the HOP concentration 
that showed the highest binding activity. 
iii. Peptide sequence analysis and down-selection 
Plasmid DNA from ≈200 bacterial colonies was sequenced from the final sorting 
round, from which 83 unique sequences were identified using Geneious. Three 
additional peptides that demonstrated PE reactivity and specificity in an earlier 
screening round were incorporated into the motifs identified by inspection (Figure 2-
1C). The binding activity, or fold fluorescence over a negative control (empty 
scaffold), of each library peptide and the AT1 epitope clone was measured in 
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 duplicate with discovery set PE and HOP (n=6 each) pools.  After incubation with 
each antibody pool (1 μmol/L), cells were labeled using biotinylated anti-human IgA 
+ IgG + IgM (Jackson ImmunoResearch), followed by streptavidin-conjugated R-
phycoerythrin.  On average, peptides exhibited 1.4-fold increased PE antibody-
binding activity compared with HOP.  Therefore peptides demonstrating 50% higher 
PE reactivity over HOP (1.5-fold) were selected as the most specific and ranked 
according to the PE activity quotient defined as the PE-binding activity multiplied by 
the ratio of PE activity to HOP (ie, dynamic range). 
 
Figure 2-1: A 2-color screening methodology isolated a pool of pre-eclampsia (PE)-specific 
antibody-detecting peptides, enabling further characterization of individual peptides. A, After 
coincubating a bacterial displayed peptide library with 2 distinctly labeled pools of PE (red or 
 
 
green fluorophore) and unlabeled pool of healthy-outcome pregnancy (HOP) antibodies 
enriched from plasma, cells expressing peptides that bind antibodies present in both groups 
with PE were isolated. B, Subsequently, the library was coincubated with a labeled HOP
antibody pool (red) and a PE pool (green). Bacteria exhibiting only green fluorescence were 
isolated, ensuring disease specificity. C, Finally, sequence analysis of the enriched pool
identified unique peptides for motif characterization and individual peptide PE- and HOP-
binding activities (fluorescent intensity) were assessed. 
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 iv. Patient antibody reactivity assays 
The AT1 epitope and seven down-selected peptides were assayed in duplicate 
against biotinylated antibodies (1 μmol/L) enriched from individual samples of a 
validation set.  This set included 10 PE and 10 HOP from cohort 1 and 20 PE and 20 
HOP from cohort 2.  The mean cell fluorescence associated with each clone was 
divided by that of a negative control for each sample.  Although the class (PE or 
HOP) was known for cohort 1, cohort 2 samples’ classes were revealed only after 
testing peptide reactivity.  To account for the varied peptide activity range, each 
clone’s binding activity was standardized by the average reactivity and standard 
deviation.   
v. Testing for mimicry of the known AT1 epitope 
To determine whether library-isolated peptides were mimicking the known AT1 
epitope, E. coli displaying the AFHYESQ epitope were used to deplete binding 
antibodies, and reactivity with the indicated library-isolated clones was measured.  
The PE antibody pool (1 µmol/L) used for down-selection was incubated with AT1 
epitope expressing cells (1x108 cells/µL). Cells were centrifuged, and the AT1-AA 
depleted supernatant was retained and assayed against library-isolated peptides and 
the AT1 epitope clone.  
vi. Identifying candidate antigens 
The motifs identified by inspection were used to perform protein database 
searches using NCBI blastp and ScanProsite of the human proteome.  After applying 
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 a similarity scoring metric, the top 80% of extracellular protein hits from each search 
were compiled into a list of candidate antigens with the corresponding fragment. 
vii. Statistical Analysis 
A subset (20 cohort 1 and 20 randomly selected cohort 2 samples) of the 60 
samples not used for discovery was used to train a classification algorithm followed 
by testing with a validation set (20 remaining cohort 2 samples) to verify peptide 
panel diagnostic accuracy.  To reduce overfitting to the training set, an Adaptive 
Boosting (AdaBoost) classification algorithm, which applies the algorithm 
successively to reweighted versions of the training set,161 was implemented through 
the ada package in R177 using a 4-split tree.  Diagnostic algorithms were generated 
with and without the AT1 epitope included in the peptide panel.  Three trials of ten-
fold cross-validation across a combined set from both cohorts (n=40) yielded each 
sample’s averaged probability for PE classification, which was used to perform 
receiver operating characteristic (ROC) curve analysis with the pROC R package and 
assess algorithm accuracy.  Additional algorithms were trained using cohort 1 or 2 
separately with or without the AT1 epitope.  Subsequently, the performance of the 6 
algorithms was assessed by generating ROC curves and determining the PE, HOP, 
and overall classification accuracy at a 0.5 probability cutoff in the final validation 
set.   
Separately, ROC analysis was performed with Prism 4 software (GraphPad 
Software Inc.) for each library-isolated peptide across the entire set of 60 validation 
samples based upon binding activity.  ROC analysis of the AT1 epitope was 
performed on the same 60 samples for comparison to library-isolated peptides 
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 followed by analysis across the entire set of 45 PE and 48 HOP samples described in 
this study.  Excluding Figures 3 and 4, data are presented as mean±SEM.  Statistical 
significance using a Student t-test or Mann-Whitney U-test and Spearman correlation 
were assessed with Prism 4 software.  For all analyses, P<0.05 was considered 
significant.  
C. Results 
i. Identification of peptides binding to plasma antibodies from PE patients 
The 45 PE samples used in this study reflect the heterogeneity of PE presentation 
including early- and late-onset PE cases and atypical severe cases without proteinuria 
(Table 2-1).  To identify PE-specific antibody-detecting peptide reagents within this 
diverse group, a bacterial display library was screened for peptides that bind 
antibodies present in multiple PE patients but not HOP subjects. This screening 
strategy used fluorescence-activated cell sorting to quantitatively measure the 
enrichment of PE antibody-binding peptides from 7% to 87% (Figure 2-2 A,B) of the 
bacterial cell population and reduction of HOP antibody-reactive peptides (Figure 2-
2 C,D).  From this enriched pool, DNA sequencing identified 83 unique peptides, 
enabling further characterization of each member alongside 3 peptides from an earlier 
screening round.  None of the library-isolated peptides were similar to the known AT1 
receptor epitope AFHYESQ, but several different motifs were identified (Table 2-2).  
Three motifs (a-1 to a-3) were similar, and 4 additional motifs were distinct.   
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 Table 2-1: Clinical characteristics of patients 
 Discovery 
Samples 
(Cohort 1) 
Training  
Samples 
(Cohort 1) 
Training  
Samples 
(Cohort 2) 
Validation 
Samples 
(Cohort 2) 
Patient 
Characteristics 
HOP 
(n=18) 
PE 
(n=15)
HOP 
(n=10)
PE 
(n=10)
HOP 
(n=12)
PE 
(n=8) 
HOP 
(n=8) 
PE 
(n=12)
Age, yr 29.8 
(1.6) 
29.9 
(2.0) 
27.9 
(2.7) 
30.1 
(2.6) 
26.6 
(1.7) 
25.1 
(2.1) 
25.5 
(2.2) 
26.5 
(1.3) 
GAD, wk 38.0 
(0.7) 
35.3 
(0.8) 
38.9 
(0.4) 
36.8 
(0.9) 
39.1 
(0.5) 
34.8 
(1.2) 
39.6 
(0.3) 
35.7 
(0.6) 
Highest SBP, 
mm Hg 
112.0 
(3.3) 
164.7* 
(5.0) 
114.4 
(3.3) 
161.1* 
(6.8) 
113.1 
(3.4) 
156.3* 
(6.1) 
124.1 
(2.7) 
152.3* 
(5.4) 
Highest DBP, 
mm Hg 
65.4 
(2.2) 
100.2* 
(2.2) 
64.4 
(1.9) 
101.7* 
(1.7) 
66.5 
(2.8) 
94.3* 
(4.2) 
73.9 
(2.0) 
89.8† 
(3.9) 
Proteinuria, 
n (%) 
3 (17%) 13 
(87%)‡
0 (0%) 8 
(80%)‡
0 (0%) 6 (75%) 1 (13%) 7 (58%)
AST > 70 IU/mL,
n (%) 
ND 6 (40%) ND 2 
(20%)
ND 0  ND 0 
ALT > 70 IU/mL,
n (%) 
ND 6 (40%) ND 1 
(10%)
ND 0 ND 1 (8%)
Platelets < 105 
U/mL, n (%) 
0 4 (27%) 0 2 
(20%)
1 (8%) 0 0 1 (8%)
CNS Symptoms,  
n (%) 
1 (6%) 7 (47%) 0 4 
(40%)
1 (8%) 4 (50%) 0 4 (33%)
Epigastric Pain,  
n (%) 
0 3 (20%) 0 2 
(20%)
0 1 (13%) 0 0 
Birth weight, kg ND ND ND ND 3.2 
(0.16) 
2.5 
(0.32) 
3.5 
(0.15) 
2.9* 
(0.22) 
Pre-existing 
Conditions, n (%) 
        
Diabetes T1 ND ND ND ND 0 2 (25%) 0 0 
Diabetes T2 ND ND ND ND 0 0 0 1 (8%)
Lupus 0 0 0 0 0 0 0 0 
Hypertension 0 0 0 0 0 0 0 2 (17%)
Ethnicity, n (%)         
White ND ND ND ND 4 (33%) 2 (25%) 4 (50%) 4 (33%)
Hispanic ND ND ND ND 0 1 (13%) 2 (25%) 1 (8%)
Black  ND ND ND ND 8 (67%) 5 (63%) 2 (25%) 7 (58%)
 
Data are given as the mean (SEM) unless otherwise indicated. PE, pre-eclampsia; HOP, 
healthy-outcome pregnancy; GAD, gestational age at delivery; SBP, systolic blood pressure;
DBP, diastolic blood pressure; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase; CNS, central nervous system. 
* and † indicate a significant difference (P<0.01 and P<0.05, respectively) compared to HOP 
using a Mann-Whitney U-test; ‡PE subjects without proteinuria met the American College for 
Obstetricians and Gynecologists criteria for severe PE.  
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Figure 2-2: Library screening resulted in a PE cross-reactive and specific peptide population. 
Cross-reactivity sorts enriched for peptides that simultaneously bind antibodies present in two
PE groups separately labeled with a red or green fluorophore while competing with an 
unlabeled HOP pool.  A, Prior to FACS, only 7% of the peptide library population showed
cross-reactive binding; however, B, after nine rounds of sorting, 87% bound antibodies
present in two PE groups.  Further sorting rounds focused on enhancing PE specificity using
a red labeled HOP pool and green PE pool.  C, While initially 53% of the PE cross-reactive 
population also bound antibodies in the HOP pool, D, the final library population 
demonstrated high specificity with 78% binding only to the PE antibody pool and 8% also
binding the HOP antibody pool.  Gates were set according to single color and negative
control populations. 
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The library peptide consensus sequence motifs were not sufficiently strong to 
enable identification of antigens that elicited the antibodies.  Roughly 48 candidate 
autoantigens were identified by rank-ordering proteins with high similarity scores 
obtained using blastp and ScanProsite searches (Table 2-3); however, a much larger 
number of non-self proteins in the entire database also carried these motifs. 
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The respective motif name and consensus sequence is shown.  Names indicated 
correspond to peptides with 1.5-fold higher PE activity than HOP 
Consensus: WGWGXXR/K
Consensus: RG/SG/-WWG/S
Motif Sequence      Name
33
22
34
20
15
27
35
13
11
5
28
38
36
37
a-2 25
21
2
19
31
6
Consensus: RWWG/S
Consensus: RWWWG/P
Motif Sequence      Name
a-3
16
b 12
3
17
c 10
14
4
30
1
d 26
23
29
18
e
9
7
8
32
24
Consensus: WWG/-WR/K
Consensus: RWLG/S
Consensus: WGXWS/-XXXR/K
a-1
Table 2-2: Peptide binding motifs
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 Table 2-3: Candidate autoantigens mimicked by library peptides 
Human Protein Sequence Similarity 
Motif a-1 and a-2: RG/SG/-WWG/S and 
RWWG/S  
Mucin-3A GVRAVRSGWWGGQRRGR 
Angiopoietin-related protein 6 CALYQRGGWWYHACAH 
Angiopoietin-related protein 1 CAHFHKGGWWYNACAH 
Angiopoietin-related protein 2 AHYQKGGWWYNACAH 
Carboxypeptidase Z SADGSKPWWWSYFTSL 
Atrial natriuretic peptide receptor 2 YSGAEKQIWWTGRPIP 
Apolipoprotein L1 TMDYGKKWWTQAQAH 
Scavenger receptor class F, member 1 GRCACRPGWWGPECQQ 
Zona pellucida glycoprotein 2  MACRQRGGSWSPSGWF 
Skeletal muscle chloride channel protein 1 
(several isoforms) RSQQRGGEQSWWGSDPQY 
Angiopoietin-like 3 CPEGYSGGWWWHDECG 
Tubulointerstitial nephritis antigen-like 1 QGCRGGRLDGAWWFLRR  
cadherin, EGF LAG seven-pass G-type 
receptor 3 DQQCPRGWWGSPTCG 
Voltage-dependent L-type calcium channel 
subunit alpha-1S NGSECRGGWPGPNHGI 
Claudin 16 VSTKCRGLWWECVTNA 
Solute carrier family 22, member 3  APLVPCRGGWRYAQA 
G protein-coupled receptor 113 DHSLFQGRGGWSKEGCQ   
Proline-rich protein 24 RGGGGAWWGRGLCGLR  
Immunoglobulin heavy chain variable region RGWSSINGGPVECG 
Glutamate [NMDA] receptor subunit epsilon-4 HDGLDGGWWAPPPPP 
Mucin 3B, cell surface associated GVRAVRSEWWG  
GQRRGRSWDQDRK   
Cadherin, EGF LAG seven-pass G-type 
receptor 1 GWWGNPVCG 
SH3 and PX domain-containing protein 2A GISFRGGQKAEVIDKNSGGWWYV
T-cell receptor beta chain VJ region SGQARGSWCSVSAGCWG  
MRC2 mannose receptor, C type 2 LQSYEGQSRGAWLGMNFN  
A disintegrin and metalloproteinase with 
thrombospondin motifs 7 QPCPARWWAGEWQ 
Extracellular calcium-sensing receptor SFHRKWWGLNLQ 
Proto-oncogene Wnt-1 AANSSGRWWGIVNVA 
Poliovirus receptor-related protein 1 AGAAGRWWGLALGL 
Bestrophin-2 TLVVNRWWSQYLCM 
G protein-coupled receptor 139 WWSPGSACGL 
A disintegrin and metalloproteinase with 
thrombospondin motifs 17 WSPWGAWSMCSRTCG 
ADAMTS-like protein 1 WDAWGPWSECSRTCG 
ADAMTS-like protein 3 WDAWGDWSDCSRTCG 
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 Table 2-3: Continued 
Human Protein Sequence Similarity 
Motif  c,d, e: WGWGXXR/K ,WWG/-WR/K, 
and WGXWS/-XXXR/K 
 
Properdin WDSWGEWSPCIRRNM 
PPCPVAGGWGPWGPVS  
SCO-spondin WGPWGPWSHCSRSCG 
Thrombospondin type-1 domain-containing 
protein 4 GVWGAWGPWSACSRSCSG 
Anion exchange protein 3 (Gene SLC4A3) APPHAWGRWSPGEKPEAA 
Semaphorin-5B  ASWGSWSKCSS  
AWGPWSSCSRDCE 
Brain-specific angiogenesis inhibitor 2 WEEWGSWSLCSRSCV 
Brain-specific angiogenesis inhibitor 3 NQWGHWSGCSKSCD 
Catechol-O-methyl transferase LLRHWGWGLCLIGWNE 
placenta apolipoprotein B48 receptor type 2  SAVEQTWGWGDGSSHGS 
Potassium voltage-gated channel isoform 1 AERKRWGWGRLPGAR 
Scavenger receptor cysteine rich domain 
containing, group B PQLDEKRWGWRLGDGSAA 
Anaplastic lymphoma receptor tyrosine kinase CPQAMKKWGWETRGGFG 
RCC1 domain containing 1 RTGELYTWGWGKYGQLGH 
von Willebrand factor C domain-containing 
protein 2-like GDWWKPAQCSKRE  
 
In total, 38 of 86 novel peptides and the AT1 epitope exhibited an average 1.5-
fold increased PE-binding activity compared with HOP, and these peptides were 
ranked according to their PE-specific antibody-binding activity (ie, activity quotient; 
Figure 2-3).  The most PE-specific and reactive peptides exhibited an activity 
quotient of ≥6, and the most highly represented motifs among these peptides were 
determined (Figure 2-4).  The greatest fraction (10/22) of peptides with a high PE 
activity quotient represented the a-1 motif (RG/SG/-WWG/S), which was also 
comprised of the greatest number of unique peptides.  Individual peptides from these 
motifs did not exhibit reduced PE antibody binding after depletion with the AT1 
epitope AFHYESQ (Figure 2-5), indicating that library-isolated peptides did not 
mimic the AT1 epitope. 
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  B A 
 
 
 
Figure 2-3:  The AT1 epitope and 38 library-isolated peptides showed PE reactivity and 
specificity. A, Activity quotient, q=(PE Activity)2/HOP Activity, is shown for all peptides 
exhibiting 1.5-fold increased PE binding activity over HOP with B, the corresponding PE and 
HOP binding activity.  Peptides from an earlier screening round separated above the AT1
epitope.    * p < 0.05 one-tailed t-test
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Figure 2-5: Comparison of antibody reactivity before and after AT1-AA depletion indicates 
distinct specificities. The reactivity of each of the library-isolated peptides analyzed was not 
significantly decreased by AT1-AA depletion. However, the significant loss in binding activity
to the AT1 epitope confirmed appropriate depletion of AT1-AAs from the sample (n=6). 
Figure 2-4: Consensus library peptides recognized by pre-eclampsia (PE)-specific antibodies. 
Twenty-two peptides exhibited a high-reactivity quotient (q>6) and were grouped according to 
consensus families, indicated on the right. q=(PE Activity)2/HOP Activity 
 48
 ii. Peptides demonstrate diagnostic ability on a validation set 
To assess the diagnostic efficacy of these PE-specific peptides, seven library-
isolated peptides with PE activity quotients >6 and the AT1 epitope were tested for 
reactivity against 30 new PE and 30 HOP patients. Together, the panel of library-
isolated peptides performed well, achieving 100% accuracy within the cohort 1 
validation set (Figure 2-6), whereas the AT1 epitope alone accurately classified 6 of 
10 PE and 9 of 10 HOP in cohort 1.   
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Figure 2-6: The library-isolated peptides demonstrated strong classification accuracy in a
new set of PE and HOP cohort 1 samples. A, All peptides, including the AT1 epitope 
demonstrated significantly higher PE binding activity than the controls using the Mann-
Whitney U-test (*) or Student’s t-test (†).  B, The heat map shows that these peptides are 
highly cross-reactive with PE patients while remaining specific. C, Summing the 
standardized activity of the library peptides enables 100% diagnostic accuracy. * or † 
p<0.05; ** or †† p<0.001. 
Cross-validation trials across the combined set of both cohorts (n=40) using 
library-isolated peptides with and without the AT1 epitope yielded averaged areas 
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 under the curve (AUC) of 0.78 and 0.72, respectively (Figure 2-7), achieving 61% 
(95% confidence interval, 36-83%) sensitivity at 95% (95% confidence interval, 77-
100%) specificity (Table 2-4).  Comparatively, the AT1 epitope alone demonstrated 
an AUC of 0.65 in this set of 40 samples and at 61% sensitivity exhibited 55% (95% 
confidence interval, 32-76%) specificity. 
 
Figure 2-7: Receiver operating characteristic (ROC) curves are shown for algorithm 
predictions using library peptides with and without the angiotensin II type 1 receptor (AT1) 
epitope and the AT1 epitope alone across the combined training sample set (n=40). The
respective areas underneath the ROC curves are also indicated in parantheses. 
 
Next, the classification accuracy of algorithms trained using cohort 1, cohort 2, or 
the combined set with and without the AT1 epitope was assessed using an external 
validation set (20 remaining cohort 2 samples).  The ROC curves of all 6 predictive 
algorithms revealed that use of samples from both cohorts in training resulted in the 
highest AUC, especially when including the AT1 epitope (0.83; Figure 2-8).  The 
algorithm trained using only the library peptides with the combined set attained a 
similar AUC (0.78), and both algorithms achieved comparable overall accuracy, 75% 
and 80%, respectively, at the prescribed cutoff.  Although the algorithm including the 
AT1 epitope yielded only 1 false-positive, it misclassified 2 more PE samples than the 
algorithm using only library peptides (Table 2-5). 
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 Table 2-4: Average algorithm predictions 
 With AT1 Epitope Without AT1 Epitope 
Sample ID Average SEM Average SEM 
PE 1-1 0.10 0.03 0.16 0.13 
PE 1-2 0.84 0.09 0.89 0.07 
PE 1-3 0.70 0.13 0.75 0.11 
PE 1-4 0.81 0.08 0.98 0.01 
PE 1-5 0.74 0.04 0.74 0.11 
PE 1-6 0.78 0.10 0.85 0.05 
PE 1-7 0.39 0.06 0.32 0.19 
PE 1-8 0.75 0.11 0.83 0.05 
PE 1-9 0.79 0.05 0.81 0.08 
PE 1-10 0.71 0.08 0.63 0.02 
HOP 1-1 0.13 0.11 0.06 0.03 
HOP 1-2 0.20 0.07 0.05 0.03 
HOP 1-3 0.03 0.01 0.03 0.01 
HOP 1-4 0.25 0.06 0.05 0.04 
HOP 1-5 0.36 0.04 0.31 0.06 
HOP 1-6 0.06 0.04 0.09 0.03 
HOP 1-7 0.26 0.08 0.26 0.10 
HOP 1-8 0.16 0.07 0.34 0.07 
HOP 1-9 0.06 0.02 0.19 0.08 
HOP 1-10 0.38 0.18 0.49 0.08 
PE 2-1 0.82 0.08 0.88 0.03 
PE 2-2 0.65 0.10 0.72 0.01 
PE 2-3 0.36 0.12 0.34 0.13 
PE 2-4 0.13 0.08 0.08 0.05 
PE 2-5 0.73 0.06 0.87 0.08 
PE 2-6 0.17 0.09 0.22 0.08 
PE 2-7 0.30 0.07 0.07 0.03 
PE 2-8 0.24 0.13 0.13 0.05 
HOP 2-1 0.36 0.05 0.29 0.19 
HOP 2-2 0.31 0.10 0.40 0.05 
HOP 2-3 0.26 0.10 0.38 0.01 
HOP 2-4 0.45 0.25 0.38 0.04 
HOP 2-5 0.11 0.04 0.19 0.03 
HOP 2-6 0.30 0.10 0.30 0.06 
HOP 2-7 0.91 0.05 0.91 0.08 
HOP 2-8 0.34 0.03 0.29 0.11 
HOP 2-9 0.34 0.07 0.39 0.06 
HOP 2-10 0.08 0.03 0.24 0.04 
HOP 2-11 0.16 0.04 0.33 0.09 
HOP 2-12 0.32 0.14 0.24 0.02 
Sensitivity 61% 61% 
Specificity 95% 95% 
Accuracy 80% 80% 
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 Finally, classification accuracy was not significantly different when analysis was 
restricted to cases of PE (n=19) identified strictly by proteinuria and no pre-existing 
hypertension.  The array algorithm excluding the AT1 epitope correctly detected 12 
(63%) subjects of this PE subgroup, compared to 70% in the full, more heterogeneous 
group (n=30).  
Table 2-5: Classification algorithm performance 
Training Set 
PE 
(n/N) 
HOP 
(n/N) 
Overall 
(n/N) 
Library Peptides and AT1 epitope       
Cohort 1 4/12 (33%) 7/8(88%) 11/20 (55%) 
Cohort 2 8/12 (67%) 5/8 (63%) 13/20 (65%) 
Combined 8/12 (67%) 7/8 (88%) 15/20 (75%) 
Library Peptides    
Cohort 1 7/12 (58%) 5/8 (63%) 12/20 (60%) 
Cohort 2 5/12 (42%) 7/8 (88%) 12/20 (60%) 
Combined 10/12 (83%) 6/8 (75%) 16/20 (80%) 
 
In addition to evaluating overall diagnostic performance, the antibody-detecting 
peptide algorithm was assessed for adverse outcome detection use.  Because of the 
Figure 2-8:  Receiver operating characteristic (ROC) curves demonstrated improved 
performance using the combined set of samples in a validation set. ROC curves were 
generated for algorithms A, with or B, without the AT1 epitope in the peptide panel against 
the final 20 samples from cohort 2.  The algorithms were trained using samples from 
cohort 1, cohort 2, or the combined set.  The areas underneath the curves (AUC) are also 
indicated.   
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 inclusion criteria used in this study, 6 of 30 patients with PE used in training and 
validation exhibited severe symptoms, such as central nervous system disturbances, 
thrombocytopenia, and elevated liver enzymes, without proteinuria.  Importantly, the 
antibody-detecting peptide panel identified 5 of these 6 atypical patients with PE.  
Furthermore, the peptide panel detected 5 of 6 nonproteinuric patients with PE that 
delivered before 37 weeks’ gestation (n=18; Table 2-6). This could help stratify 
patients requiring more timely delivery thereby complementing severe symptom 
detection.  Overall, combining clinical criteria of high BP and proteinuria along with 
the antibody-detecting peptide panel achieved the highest sensitivity for severe 
symptoms and early delivery. 
Table 2-6: Association of antibody-detecting peptide panel reactivity with 
adverse outcomes. 
Detection method 
Severe symptoms
(n=16) 
Early delivery (<37 weeks) 
(n=18) 
Proteinuria 10 (63%) 12 (61%) 
Peptide panel (+AT1 epitope) 12 (75%) 12 (67%) 
Peptide panel 13 (81%)  13 (72%) 
Proteinuria + Peptide panel 15 (94%) 17 (94%) 
 
Severe symptoms include central nervous system disturbances, elevated liver enzymes, 
and/or thrombocytopenia.  Proteinuria refers to patients with pre-eclampsia with positive 
proteinuria. AT1 indicates angiotensin II type 1 receptor 
iii. Statistical analysis of individual peptide performance 
Individual peptides constituting the panel exhibited differing diagnostic efficacy.  
The AT1 epitope exhibited significantly (P<0.05) higher PE antibody binding when 
evaluated across the entire sample set (45 PE and 48 HOP; Figure 2-9).  Here, the 
AT1 epitope detected binding antibodies in 78% of PE and 44% of HOP, resulting in 
an AUC of 0.66. However, binding of antibodies from subjects with PE to the AT1 
epitope was not significantly increased in the validation set composed of 60 samples. 
In contrast, 5 library-isolated peptides exhibited significantly (P<0.05) higher 
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 reactivity with PE samples than with HOP samples (Figure 2-10A). In addition, 
library-isolated peptides achieved comparable or higher AUCs than the AT1 epitope.  
Peptides cross-reacted with multiple PE patient antibodies, and antibodies from PE 
that reacted strongly with one peptide tended to bind multiple peptides (Figure 2-
10B). Similarly, HOP antibodies that reacted with one peptide also tended to bind 
multiple peptides including the AT1 epitope.  Nevertheless, the 7-member panel 
exhibited stronger diagnostic efficacy than any individual peptide.  Interestingly, 
peptide binding activity, especially peptide 36 (rs=-0.62), inversely correlated with 
PE patient platelet count in this set (Figure 2-11).  Summing the standardized binding 
activity of the 7 library-isolated peptides and AT1 epitope yielded the overall 
correlation (rs=-0.56) with platelet count. Analysis of other patient characteristics (ie, 
BP or proteinuria) did not reveal strong correlations with peptide standardized 
reactivity.  
Figure 2-9: AT1-AA detection in the entire set of 45 PE and 48 HOP samples.  A. Binding 
activity of the cell-surface expressed AT1 epitope and B. the ROC analysis which yielded an 
AUC of 0.66. Mann-Whitney U-test (**), Student’s t-test (†) where † p<0.05, ** p<0.01 
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  55
 
 
Figure 2-10: Library-isolated peptides and the angiotensin II type 1 receptor (AT1) epitope 
demonstrate cross-reactivity with pre-eclampsia (PE) patients and decreased healthy-
outcome pregnancy (HOP) binding.  A, Peptide reactivity with 30 samples each of PE and 
HOP in a dot plot, where lines represent the mean of the population. Area underneath the 
ROC curve is also indicated for each peptide in parantheses. B, A heat map shows cross-
reactivity and application as a peptide panel.  Statistical significance indicated for Mann-
Whitney U-test (*), Student t-test (†) where applicable. * or † P<0.05, ** or †† P<0.01 
Standardized reactivity=(sample fluorescence–average fluorescence)/SD of fluorescence. 
 
  
D. Discussion 
In this study, we present evidence that PE is associated with a distinctive 
signature of antibody-binding specificities.  This signature was represented in a PE 
antibody-detecting peptide panel composed of multiple epitope specificities.  One 
such specificity corresponds to a 7-mer epitope of the AT1 receptor.2  The 
pathobiological significance of these AT1-AAs is now supported by multiple 
es
ould play a role in PE pathology.  The pursuit for additional PE antibody markers 
has identified an association between PE and antibodies binding various autoantigens, 
including β1, β2 and α1 adrenoreceptors,128 cardiolipin,129 and prothrombin.130  
However, the use of unbiased discovery approaches to characterize the complete 
) 
independent studies, demonstrating their ability to increase BP, proteinuria, and sFlt-
13 and complement deposition.173  Despite this increased complement deposition in 
the placenta and kidney of pregnant mice, blocking the AT1 receptor did not fully 
reduce deposition to HOP levels, leaving open the possibility that other antibodi  
c
Figure 2-11: Peptide binding activity is inversely correlated with the platelet counts in PE
patients.  The strongest correlation observed with peptide 36 and the summed standardized
reactivity for all eight peptides, including the AT1 epitope, are shown. rs=Spearman correlation 
coefficient   
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 antibody repertoire has not been described.  Furthermore, the antigens responsible for 
eliciting these autoantibodies have not been determined, and their binding epitope 
specificities remain uncharacterized.  Using an unbiased antibody repertoire analysis 
method, we observed a unique epitope reactivity pattern and used representative 
peptides to develop a PE antibody-detecting panel for diagnosis.  In spite of the 
strong evidence for AT1-AAs in PE, we did not identify peptides with similarity to 
the AT1 epitope AFHYESQ.  This result might be explained by an insufficient 
nonpregnant normotensive subjects.178  Although the mechanism responsible for the 
PE antibody signature is unclear, the reduced prevalence of T-regulatory cells in 
PE1
1
1
1
1 e
antibody affinity or titer, or the high frequency of AT1-AA in HOP subjects (used for 
subtraction) in this and previous studies135,136 and overall increased activity over 
23 may contribute to elevated autoantibody production.  In addition, the 
observation that several nonself proteins also carry these motifs raises the possibility 
that the antibodies may originally be responding to an environmental trigger as 
previously proposed for AT -AAs.135  Regardless of the production mechanism, this 
study supports an altered immune response in PE pathophysiology by verifying the 
presence of PE-specific antibodies in addition to AT -AAs that could be useful for 
diagnosis. 
Despite the demonstrated role of AT -AAs in PE and potential for use in 
diagnosis and guiding therapy, their detection has proven exceptionally difficult.  
Current detection techniques rely upon complex biologic function assays,2,138 that are 
unlikely to be effective for point-of-care diagnosis.  To address this problem, we 
developed a unique binding assay for AT -AA detection using the 7-mer epitop  
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 displayed in a high-avidity format on the bacterial cell surface.  One recent study 
demonstrated higher AT1-AA titers in PE patients (n=13) over HOPs (n=30) using the 
27-aa second extracellular loop in an ELISA;178 however, here the cell-displayed 7-
mer was sufficient to detect epitope specific antibodies in 78% of PE patients and 
44% of HOP (45 PE and 48 HOP).  Thus, AT1-AA detection can be performed with 
the 7-mer and does not require the entire loop.  Assays based upon the minimal 7-mer 
may be important for developing therapeutics designed to block this antibody 
specificity3 and differentiate this from specificities present in other diseases such as 
renal allograft rejection.174  For comparison, a biologic function assay identified AT1-
AAs in ≈70% of patients with PE and 20% of HOPs135 in addition to 62% of HOPs 
with abnormal perfusion.136  The percentage of HOP subjects in our study that 
experienced abnormal perfusion during pregnancy is not known because the test is 
not part of routine practice.  Regardless, these results demonstrate the use of an 
epitope-specific binding assay for AT1-AA detection in patients with PE, for which 
researchers have previously relied upon complex biologic function assays.  
The 7-member PE antibody-detecting panel demonstrated a potential use for 
detecting PE cases that is comparable with current protein biomarkers.  The peptide 
panel exhibited 100% accuracy in the validation set from cohort 1 and maintained 
strong accuracy (80%) despite the inclusion of a second cohort from a distinct 
geographic location, which affects a population’s antibody repertoire.179 Despite this 
effect, the panel exhibited comparable diagnostic efficacy to biomarkers in clinical 
development, such as sFlt-1 and PlGF.  Studies evaluating these markers have 
primarily focused on early-onset PE in which they show the strongest accuracy; 
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 however, the accuracy drops in late-onset (≥34 weeks) PE.180  Commercially 
available diagnostic kits for the sFlt-1/PlGf ratio and PlGF alone exhibited 59% 
sensitivity at 100% specificity and 77% sensitivity at 95% specificity, respectively, 
across all gestational onsets.169  Similarly, this study did not discriminate between 
early- and late-onset and the antibody-detecting peptide panel achieved 61% 
sensitivity at 95% specificity within the cross-validated training set.  It remains to be 
determined whether the PE-specific peptide panel can perform similarly in larger 
cohorts.  Nevertheless, our results indicate that a PE antibody-detecting peptide panel 
can effectively discriminate PE and HOP samples and demonstrate that PE patients 
possess a distinctive antibody repertoire signature.   
This PE-specific antibody signature was associated with an increased detection of 
adverse outcomes.  A substantial percentage of patients who develop HELLP 
syndrome (10%-15%) or eclampsia (20%-25%) are not detected by the current 
clinical criteria of hypertension and proteinuria.139   Thus, there exists an unmet need 
to identify those at risk of developing these adverse outcomes.  The antibody-
detecting peptide panel outperformed (81%) clinical criteria (63%) in detecting 
patients (n=16) with severe PE characterized by symptoms of central nervous system 
disturbances, elevated liver enzymes, and thrombocytopenia, suggesting that this 
antibody signature is more strongly associated with these severe PE symtpoms.  
Furthermore, peptide binding activity inversely correlated with platelet levels.  
Continued investigation of this association may link a pathophysiological role for 
these antibodies to these severe symptoms.  
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 E. Perspectives 
Here, we demonstrated the existence of antibody biomarkers present in PE 
patients distinct from known AT1-AAs that achieve strong diagnostic accuracy (80%) 
for PE.  Thus, our results provide supporting evidence for an altered immune 
response in PE.  Identifying the antigen(s) mimicked by our library-isolated peptides 
may enable characterization of the antibody’s contribution to PE pathogenesis while 
elucidating potential therapeutic targets.  Furthermore, use of the whole or partial 
antigen(s) mimicked by library peptides may further increase sensitivity/specificity of 
the assay.  In addition, the ability to detect PE early in pregnancy before clinical 
presentation would aid patient management.  A time-course study using the PE 
anti
ion was developed using bacterial cells 
that display on their surface the 7-mer AT1 epitope. 
body-detecting peptides described here could identify when these antibodies first 
present to assess their potential use in the early diagnosis of PE.  Finally, because this 
methodology does not require purified antibodies, screening can be conducted using 
unprocessed, diluted plasma to identify peptide diagnostic reagents that bind PE 
specific antibodies without the additional purification step. 
 
 Novelty and Significance 
What is New? 
• This study identified antibody specificities that occur in pregnant women with 
pre-eclampsia (PE) that are distinct from known angiotensin II type 1 receptor 
(AT1) autoantibodies (AT1-AAs) with use for PE diagnosis. 
• A binding assay for AT1-AA detect
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 What is Relevant? 
ays.  
• This peptide panel diagnostic assay demonstrated a high specificity (95%) at 
61% sensitivity in the training set and maintained 80% accuracy in an 
independent validation set. 
• Further characterization may identify antigen(s) mimicked by these PE-
specific peptides potentially leading to novel therapeutic targets. 
• The improved throughput of the binding assay for AT1-AA detection will 
enable larger cohort studies to improve understanding of their prevalence in 
PE and HOP. 
Summary 
PE-specific antibody-detecting peptides isolated from a bacterial display library 
exhibited strong diagnostic efficacy within independent sample sets from distinct 
geographic locations.  Using a unique AT1-AA detection assay the prevalence of 
AT1-AA in subjects with PE and HOP was comparable with that observed in previous 
studies using more complex biological function based bioass
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 3. A pre-eclampsia associated Epstein-Barr virus antibody cross-reacts with 
placental GPR50 
 
While the human antibody repertoire reflects immune responses to diverse prior 
environmental exposures, it remains difficult to identify disease-associated antibodies 
and the environmental antigens eliciting these antibodies. To discover environmental 
antigens associated with pre-eclampsia (PE), bacterial display peptide library 
screening and evolution was applied to identify peptide epitopes recognized by 
antibodies occurring in women with PE. This strategy revealed that women with PE 
near delivery exhibit elevated IgG1 titers directed towards motif KXXXC[VIL]GCK 
present in the Epstein-Barr virus nuclear antigen (EBNA-1).  Interestingly, the 
EBNA-1 epitope specific antibodies cross-reacted with a similar epitope within the 
extracellular N-terminus of the human G protein-coupled receptor, GPR50.  GPR50 
was strongly expressed in human placental tissue and found in immortalized placental 
trophoblast cells. Peptide epitopes derived from EBNA-1 and GPR50 exhibited 
significantly higher antibody binding activity among PE patients near delivery 
compared to that observed for healthy-outcome pregnancies at term and nulligravid 
samples. The EBNA-1 peptide potently blocked (IC50≈60-80 pM) binding of the PE-
associated antibody to the peptide epitope within GPR50.  These results reveal the 
existence of sequence level molecular mimicry between EBNA-1 and placental 
GPR50, indicating a mechanism for IgG1 deposition in the placenta, as a prevalent 
immunological feature of pre-eclampsia. 
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 A. Introduction  
ve environmental factors that trigger 
disease onset, propagate disease, or influence disease severity.30  However, the 
definitive identification of specific environmental factors has remained elusive in 
most cases.  Nevertheless, the identification of specific environmental factors that 
drive pathological immune responses would greatly aid in the development of 
improved molecular diagnostics and efficacious therapeutic interventions. 
Since the immune system archives environmental antigen exposures within the 
receptor repertoire of memory B- and T-cells, the identification of disease-associated 
antibodies and T-cell receptors (TCRs) and their corresponding antigen preferences 
has been pursued as a means to identify environmental factors. Antigen discovery for 
antibodies has been investigated using protein microarrays,59,181 fragment libraries 
from proteins of interest,69,182,183 and cDNA libraries from tissues or cells involved in 
pathology.70,77 TCR epitope profiling methodologies include enzyme-linked 
immunospot184 and peptide MHC class II tetramer assays.185  These methods have 
enabled identification of both validated antigens59,182-185 and novel candidate 
autoantigens.59,70,77,181,183  However, because such methods rely upon assaying 
antibody repertoires against a predefined, and often incomplete, proteome they have 
not enabled an impartial identification of environmental antigens. Massively parallel 
DNA sequencing of antibody or TCR variable domains has proven to be a powerful 
approach to characterize alterations in the B-52,186 and T-cell187,188 repertoires.  
Characteristic repertoire changes have been observed in multiple sclerosis,186 
rheumatoid arthritis,52 leukemia,187 and severe aplastic anemia.188   Recent advances 
Autoimmune diseases are thought to invol
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 have enabled autoantigenic target identification for sequenced antibodies using 
mic
age display 
scre
roarray analysis;52 however, in general, these repertoire sequencing approaches 
have not revealed environmental antigens that may elicit these molecules.  
Consequently, there remains a distinct need for methods which could identify the 
environmental antigens giving rise to pathological immune repertoires. 
Random peptide library screening does not require a priori knowledge of disease 
mechanisms and has been applied to a variety of diseases. In particular, ph
ening has been applied to inflammatory diseases,75 cancers,76 and autoimmune 
diseases.79-81  A phage displayed library screened against CD patients discovered a 
common epitope of gliadin.80  In multiple sclerosis (MS), phage display identified 
peptides that bound a higher fraction of cerebrospinal fluid antibodies in MS than in 
disease control.79 However, these screens either used few individual patient 
specimens76,79 or a single pool/patient-derived antibody for discovery.75,80,81 This 
approach inhibits selective isolation of widely prevalent antibodies in multiple 
individuals.  Furthermore, some relied on few peptide sequences79-81 to identify 
similarities with candidate viral and human antigens and used pre-existing knowledge 
to focus searches for candidate targets.  However, recent application of random 
peptide library screening impartially identified a CD-specific epitope corresponding 
to one of the hallmark environmental antigens, deamidated gliadin, through directed 
evolution.189  Since random peptide library screening requires no prior knowledge of 
the disease, we sought to apply this methodology to identify disease-associated 
antibodies and their binding targets for pe-eclampsia (PE), a disorder affecting 5-8% 
of pregnancies.1 PE causes 15-20% of maternal mortalities and morbidities in 
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 developed countries101 and approximately a half million fetal deaths worldwide each 
year.  Despite serious global impact, the etiology of PE remains largely unknown.     
While the mechanisms behind PE pathology remain unclear, several 
immunological findings have been observed in patients with PE.  Evidence suggests a 
further intensified inflammatory condition with increased levels of pro-inflammatory 
cytokines, IL-6 and IL-8, among PE patients compared to pregnant and non-pregnant 
control patients.190  Additionally, a variety of autoantibodies128,129,130 have been 
associated with PE.  Notably, PE patients produce agonistic antibodies against the 
angiotensin II type 1 receptor (AT1-AAs)2 that appear as early as 18 weeks’ 
gestation.136  These AT1-AAs induced symptoms of PE in an adoptive transfer mouse 
model3 and amplified complement protein C3 deposition in the placenta and kidney of 
pregnant mice.173  Increased C3 deposits have also been observed in placental vessels 
from a transgenic PE rat model, and addition of supernatant obtained from cultured 
PE placental explants enhanced C3 expression in rat vascular smooth muscle cells.122  
Furthermore, mutations within complement system regulatory proteins have been 
implicated in PE.118  In addition to complement system disturbances, PE patients 
exhibit significantly reduced levels of circulating123 and placental124 
CD4+CD25+FoxP3+ regulatory T-cells, which can lead to increased autoantibody 
production.125  Moreover, CD19+CD5+ B-cells, a class associated with the 
production of autoreactive antibodies,127 are elevated in PE patients.126  These 
isolated cells have been shown to produce AT1-AAs in culture upon addition of PE 
serum.  Taken together, these prior studies support an important role for the immune 
system in the pathogenesis of PE. 
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 Despite their apparent involvement in PE, previously characterized AT1-AAs are 
difficult to detect and vary in prevalence among studies, from 70%135 to 95%.138  
Pat
B. Materials and Methods 
t half of the pregnancy, ii) proteinuria using a spot 
urine check (≥30 mg/dL), dipstick reading (≥1+), or 24 hour analysis (≥300 mg/24) 
ients with PE were recently shown to possess additional disease-associated 
antibodies distinct from these AT1-AAs, although these antibodies could not be 
conclusively related to any self or environmental antigens (Chapter 2).191   Here, we 
sought to identify antigens that may be recognized by PE-associated antibodies, and 
thereby elucidate the immune mechanisms of pathogenesis.  Our results point to a 
molecular mimicry mechanism operating in PE women near delivery, wherein a viral 
antigen specific antibody cross-reacts with an abundant placental antigen. More 
generally, our study further supports the idea that bacterial display peptide library 
screening may be useful to identify environmental factors involved in human disease 
in an unbiased fashion.  
i. Patient Samples 
The majority of patient samples used in this study have been previously described 
(Chapter 2).191  Whole blood samples from pregnant women with PE or healthy-
outcome pregnancy (HOP) were provided as aliquots of samples taken for routine 
blood work during clinical assessments at the Santa Barbara Cottage Hospital.  The 
Santa Barbara Cottage Hospital Institutional Review Board approved this study.  PE 
subjects fulfilled at least two of the following criteria: i) two documented blood 
pressures (BP) with readings greater than 140/90mm Hg at least 4 hours apart, with 
documented normal BPs in the firs
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 iii) 
t the maxima observed upon PE presentation or prior to 
delivery. 
ii. Screening a randomized peptide library against dilute plasma  
A 15-mer random peptide library was displayed on the surface of Escherichia coli 
MC1061175 as a fusion to the N-terminus of the eCPX scaffold.90  Overnight 
incubation of patient derived diluted plasma (1:50) with empty library scaffold 
expressing cells removed E. coli binding antibodies from the retained supernatants.  
Using these depleted plasma samples, library screening sequentially removed 
peptides binding antibodies present in HOP samples using magnetic selection and 
enriched for peptides that bind PE plasma antibodies with fluorescence activated cell 
sorting (FACS).  Groups of three PE and three to four HOP plasma samples were 
pooled together to create six pools of each class.  After incubating with either PE or 
central nervous system (CNS) symptoms (visual disturbances or unremitting 
headaches), iv) epigastric pain associated with elevated liver enzymes unrelated to 
other abdominal pathology, v) or thrombocytopenia with platelet counts less than 
100,000 U/mL.  Additional plasma aliquots from PE, HOP and nulligravid 
individuals and tissue samples were provided from the University of Texas, Houston 
Medical School. These PE samples were diagnosed by clinical assessments based on 
the National High Blood Pressure Education Program Working Group Report.  
Superimposed PE cases (those with a previous history of hypertension) were not 
included, but this study did not discriminate between early-and late-onset PE or based 
on parity.  Subjects provided informed consent, and samples were collected according 
to institutional guidelines.  Blood samples were obtained near the time of delivery.  
Recorded BPs represen
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 HOP plasma diluted (1:100 or 1:200) in phosphate buffered saline (PBS), labeling 
proceeded with a biotinylated anti-human IgG specific secondary (Jackson 
ImmunoResearch) diluted (1:500) in PBS with 0.1% bovine serum albumin (BSA).  
Streptavidin (SA)-conjugated magnetic beads were used for magnetic depletion while 
SA conjugated to R-phycoerythrin (SA-PE) (Invitrogen) diluted (1:333) in PBS with 
0.1% BSA fluorescently labeled cells for FACS.  Incubations with plasma or labeling 
reagents were conducted at 4°C.  All PE and HOP pools were quantitatively assessed 
for binding to the library population at each round of FACS to determine which pool 
to use for enrichment or depletion.  The screening was performed in duplicate using 
the same sample pools, but in different order of depletion/enrichment.  Bacterial 
colonies (~130) were randomly selected for sequencing from different rounds of the 
duplicate screens.  Peptide binding motifs were separately determined by inspection 
of the unique sequences identified using the Geneious software package.     
To further evolve the peptide binding motif, a focused bacterial display peptide 
library of the form XXXKXXXC[VIL]GCXXXX was constructed.  Screening against 
this library proceeded as described above but involved three new pools each of PE 
and HOP using further diluted plasma (1:200 and 1:500).  From the focused library, 
about 100 colonies were selected for sequencing from screening rounds (primarily 
from the final round) to assess the impact of increased screening stringency upon the 
consensus motif.   
iii. Identifying the native antigen corresponding to the peptide motif 
Unbiased searches using NCBI BLASTp and ScanProsite identified candidate 
antigens and the corresponding source organism.  Three proteins were chosen as 
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 candidate environmental trigger antigens.  These fulfilled the requirements that they 
shared identities with the most common amino acids of the motif, specifically 
KXX[NSTG]C[VIL]GCK, and weren’t hypothetical proteins.  Individual 15-mer 
fragments derived from these proteins were cloned onto the N-terminus of the eCPX 
scaffold along with a C-terminal peptide tag (P2x) that binds a fluorescent reporter 
(YPet-Mona) of scaffold expression.176  The human proteome was separately 
searched to identify candidate autoantigens.  To qualify, the protein shared at least 
five identities to the searched motif.  Two of the six human protein fragments only 
differed by one amino acid, so one was selected for autoantigen assays.  These cell-
surface expressed antigen fragments and library-isolated peptides were evaluated for 
significantly increased PE binding over HOP and dynamic range for at least 15 PE 
and 15 HOP.  After incubating with diluted plasma (1:200), cells were washed twice 
with cold PBS and resuspended with biotinylated anti-human IgG (Jackson 
Imm
ristic (ROC) curve analysis was conducted using Prism 4 or 6 
software (GraphPad Software Inc.).  Epitopes with a statistically significant (p < 0.05) 
difference between PE and HOP and highest dynamic range were down-selected for 
further analysis against 42 PE and 43 HOP samples.   
unoResearch) diluted (1:500) in PBS with 0.1% BSA for secondary labeling.  
Subsequently, the cells were washed with cold PBS and resuspended in SA-PE 
diluted (1:333) in PBS with 0.1% BSA for fluorescent labeling and flow cytometric 
analysis.  The fluorescent intensity measured for each peptide was divided by the 
background intensity of the negative control, scaffold without an N-terminal peptide.  
Statistical evaluation using Student’s t-test or the Mann-Whitney U-test and receiver 
operating characte
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 iv. Analyzing full-length EBNA-1 protein activity 
PE (n=36) and HOP (n=39) samples were assayed in duplicate for antibody 
binding to full-length EBNA-1 using a commercial IgG ELISA (GenBio 
ImmunoWell) following the manufacturer’s protocol.  The Spearman correlation 
coefficient between the binding activity of bacterial displayed peptides and the 
ELISA, statistical significance (one-way U-test) of PE activity in the ELISA, and 
distribution normality (Kolmogorov-Smirnov) was evaluated in Prism 4.   
To confirm a relationship between EBNA-1 fragment (EB15) activity and the 
ELISA, EB15 binding antibodies were depleted from ten reactive PE samples, one 
reactive HOP, and nine nonreactive HOP samples and subsequently evaluated by 
ELISA.  Depletions were carried out by incubating plasma samples diluted (1:50) in 
the specimen diluent provided in the commercial kit with ~1x107 cells/μL.  The 
depleted supernatant was retained after centrifugation and evaluated for ELISA 
activity.  This was repeated for duplicate measurement. As a control, the eCPX 
scaffold with just the C-terminal tag peptide was used to “deplete” five reactive PE 
and five nonreactive HOP samples and test for ELISA activity.  Prism 4 analysis 
determined any statistically significant differences between the ELISA activity 
observed among depleted samples.    
The 15-mer EBNA-1 fragment (EB15) was synthesized, including a disulfide 
bond between the cysteine residues.  An unrelated synthetic peptide (NCP) was used 
as a negative control.  Competition assays were conducted by
v. Antibody blocking activity of the EBNA-1 synthetic peptide  
 pre-incubating pools of 
three PE patients for one hour at room temperature with varied concentrations of the 
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 syn se pools exhibited high binding 
acti
ly supplied 
vec
esuspension used PBS with 1% BSA.  Activity 
was compared to untransfected cells and an empty vector transfection control.   
Additionally, antibody binding activity was evaluated using HTR-8/SVneo cells 
cultured in RPMI (10% FBS and 1% Pen/
thesized EB15.  Selected patients included in the
vity to GPR50.  These pools were then assayed for antibody binding to the GPR50 
fragment to determine an IC50 value using Prism 4.     
To evaluate antibody binding activity to the full-length GPR50, transient 
transfections were conducted using HEK293T cells.  Cells were cultured in DMEM 
with 10% fetal bovine serum (FBS) and 1% antibiotic (Pen/Strep) prior to splitting 
for transfection, for which the Pen/Strep was removed.  The commercial
tor (OriGene, pCMV-AC-GPR50-GFP) included a C-terminal GFP tag.  Cells 
were harvested on the third day following transfection and pre-blocked for 1.5 hours 
at room temperature in PBS with 3% BSA.  After confirming GFP expression, cells 
were evaluated for GPR50 expression, using a positive control monoclonal antibody 
(R&D Systems), and binding to pools of PE patients and HOPs plasma (1:200) with 
and without EB15 (20 nM) by flow cytometry.  An anti-mouse IgG conjugated to 
Alexa647 (1:500) fluorescently tagged cells labeled with the monoclonal anti-GPR50 
(1:400), while the biotinylated anti-human IgG followed by SA-PE fluorescently 
labeled human plasma antibodies bound to cells.  Labeling reagents were diluted in 
PBS with 1% BSA.  Washes between labeling steps used PBS with 0.05% Tween20 
and 1% BSA but the final wash and r
Strep).  The immunoglobulin (Ig) fraction 
was purified from separate pools of PE and HOP plasma, exhibiting positive or 
negative antibody binding to the GPR50 fragment, respectively.  Testing these Ig 
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 pools (500 nM) with and without EB15 (20 nM) for binding to HTR-8/SVneo cells 
proceeded by flow cytometry similar to above except using an anti-human IgG 
secondary directly conjugated to R-phycoerythrin (Jackson ImmunoResearch) 
(1:1
vi. Immunohistochemistry 
Paraffin-embedded tissue sections were cleared using the xylene substitute, 
SafeClear II and dehydrated using 100%, 90%, and 70% ethanol solutions.  Antigen 
retrieval was conducted by microwaving the tissue sections for ten minutes in citrate 
buffer (pH 6).  All incubations with tissue slides were conducted in a humid chamber.  
Washes were performed two to three times each for five minutes, either with dH2O or 
PBS with 0.05% Tween20 (PBST).  In addition to a native peroxidase block, a 
blocking step using PBS with 5% normal goat serum (blocking buffer) preceded 
overnight incubation at 4°C with primary antibody either anti-GPR50 (BMA 
Biomedical) or an isotype control, mIgG1 (Southern Biotech) at 10 μg/mL diluted 
into blocking buffer.  Tissues were incubated with a biotinylated goat anti-mouse IgG 
secondary (1:200) (Vector Labs) diluted in blocking buffer at room temperature for 
one hour.  During this time, the ABC (avidin/biotinylated enzyme complex) reagent 
(Vector Labs) was mixed and allowed to sit for 30 minutes at room temperature.  
Following the secondary, tissues were incubated with the ABC reagent for 45 minutes 
at room temperature.  After adding the freshly prepared ImmPACT NovaRed HRP 
substrate (Vector Labs), the reaction continued for five minutes until stopped with 
dH2O.  Mayer’s hematoxylin counterstained the tissues, followed by dehydration 
00).  Furthermore, the GPR50 specific monoclonal antibody detected GPR50 
expression in this trophoblast cell line, as with HEK293T.      
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 with 95% and 100% ethanol, clearing and mounting with DPX mountant.  Slides 
were viewed on an Olympus BX51 microscope using the Q-Capture Pro 7 software.       
C. Results  
i. Library screening reveals an antibody response to a viral target 
To identify antigen targets of antibodies associated with PE, we screened a 
bacterial display peptide library for antibody binding using diluted plasma.  This 
study used samples from a heterogeneous set of women with PE (n=44), HOP (n=47), 
and nulligravid women (n=21) (Table 3-1).  The diverse (8x109 members) peptide 
library underwent six depletion and five enrichment rounds against a subset of the PE 
(n=18) and HOP (n=20).  This screening yielded a peptide population with increased 
binding activity to PE pools and reduced binding to HOP pools (Figure 3-1A).   
Abbreviations: SBP – systolic blood pressure, DBP – diastolic blood pressure, GAD – 
gestational age at delivery, ALT – alanine transaminase, AST – aspartate transaminase, CNS 
– central  nervous system, ND- not determined, NA – not applicable; * p < 0.0001 Mann-
Whitney U-test 
Sequence analysis identified a binding motif (KXXXC[VIL]GC) that comprised 
86% of a total of 91 unique sequences (Figure 3-2A).  This same motif was observed 
in each of two replicate screens performed in parallel, confirming reproducibility.  
Table 3-1: Clinical characteristics of patients
Patient Characteristics 
PE 
(n=44) 
HOP 
(n=47) 
Nulligravid 
(n=21) 
Age, yr 28.9 (1.2) 28.0 (1.0) 26.2 (5.6) 
GAD, wk 35.4 (0.5)* 38.8 (0.3) NA 
Highest DBP, mm Hg 97.1 (1.6)* 67.0 (1.3) 75 (7) 
ALT > 70 IU/mL, n 11 (24%) ND ND 
Platelets < 10  U/mL, n 
Highest SBP, mm Hg 159.7 (2.9)* 114.9 (1.8) 118 (11) 
Proteinuria, n (%) 35 (79%) 3 (7%) ND 
AST > 70 IU/mL, n 10 (21%) ND ND 
CNS symptoms, n 21 (48%) 2 (5%) ND 
5 6 (14%) 1 (2%) ND 
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 Further screening of a second generation (focused) library of the form 
XXXKXXXC[IVL]GCXXXX using new pools of plasma from PE and HOP cases 
led to enhanced PE cross-reactivity and specificity (Figure 3-1B).  
 
Although three pools of PE and HOP were evaluated at each round only two 
pools P (n=6) were used to select for disease-associated peptides 
through five rounds of enrichment a ion each.  The other ev
ted low binding activity.  Sequencing individual clones isolated from 
the focused library identified 43 unique sequences from the final population.  These 
sequences exhibited increased prevalence of valine in the middle position and lysine 
following the second cysteine (i.e., KXXXC[VLI]GCK Figure 3-2A).  Comparison 
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 of representative peptides from the first and second generation screens confirmed that 
directed evolution resulted in enhanced PE-specific antibody binding (Figure 3-1C). 
Searches of the nonredundant protein database with variations of this extended 
motif yielded several hits, including an N-term  epitope within the Epstein-Barr 
virus (EBV) nuclear antigen 1 (EBNA-1) K
inal
RPSCIGCK that exhibited high similarity.  
To investigate whether the identified motif mimicked the EBNA-1 epitope, bacterial 
displayed 15-mer fragments from EBNA-1 and two other candidate antigens showing 
high similarity (Table 3-2) were assayed for binding to antibodies present in PE and 
HOP samples.  The EBNA-1 fragment (EB15) demonstrated significantly increased 
binding to antibodies present in PE over HOP (Figure 3-2B).  Although another 
candidate antigen fragment, eFB, differentially bound antibodies present in PE 
compared to HOP samples, the PE antibody binding was significantly (p < 0.001) 
lower than that observed with EB15.  Furthermore, EB15 exhibited a greater dynamic 
 
 
from
range for antibody binding activity between PE and HOP samples.  While average
antibody binding to EB15 was 4.8-fold higher among PE than HOP, eFB only
showed a 2.3-fold difference.  Additionally, to correctly differentiate 91% of HOP 
 PE, EB15 detected 73% of PE (n=23, each), while the eFB fragment only 
distinguished 43% of PE.   These observations highlighted the enhanced antibody 
binding to EB15 among PE patients compared to eFB.   
In addition to the PE-specific antibody binding to the EB15 epitope, a commercial 
ELISA evaluated whether a differential trend in antibody binding continued against 
the full-length protein.  In a set of 36 PE and 39 HOP, the overall ELISA activity was 
increased (p < 0.05, one-tailed) among women with PE (Figure 3-2C).  The PE 
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 samples also exhibited a skewed distribution towards higher activity, failing the 
Kolmogorov-Smirnov normality test (p < 0.03).  The observed ELISA activity 
correlated well with antibody binding to the bacterial displayed EB15 
(rs=0.77)(Figure 3-2D). For comparison, the second generation library-derived 
peptide showed a similar correlation (rs=0.75), improved from the first generation 
peptide (rs=0.63), highlighting the gain of function obtained via directed evolution.   
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 Library screening reveals presence of antibodies directed towards an epitope of 
the Epstein-Barr virus EBNA-1 protein.  (A) Peptides from the 1 generation random library ost r 
a focused 2nd generation library were enriched for the KXXXC[VIL]GC[KR] motif. (B) 
ELISA for EBNA-1 antibodies exhibits a skewed distribution violating the Kolmogorov-
according to a one-tailed U test.  (D) ELISA signals correlated with binding activity to the 
surface displayed EB15, 1st, and 2nd generation peptides. r  – Spearman correlation 
Reactivity of three candidate antigen epitopes with PE and HOP antibodies is shown.  (C). An 
Smirnov normality test (p < 0.5). PE samples exhibited significantly (p<0.05) higher activity 
s
coefficient  
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 Antibody depletion experiments further demonstrated that the motif identified 
from random peptide library screening corresponded to antibody binding to the EB15 
epitope.  Removing antibodies binding to the displayed EB15 resulted in a complete 
loss of binding to the library peptide (Figure 3-3A), indicating these peptides bind the 
same antibody species. Additionally, the contribution of the targeted EB15 epitope to 
the commercial ELISA signal observed for the full-length EBNA-1 was assessed.  
The ELISA evaluated the residual activity of plasma samples depleted of antibodies 
binding the displayed EB15 or scaffold protein only.  Using EB15 reactive samples, 
bacterial displayed EB15 depleted plasma exhibited significantly reduced EBNA-1 
binding activity by ELISA compared to scaffold depleted plasma (Figure 3-3B).  In 
contrast, the EBNA-1 ELISA signals for plasma that did not show antibody binding 
activity to EB15 were not significantly different.  Finally, the EB15 specific antibody 
was determined, using appropriate secondary reagents, to be of the IgG1 subtype 
(Figure 3-4), indicating that it is capable of fixing complement. Taken together, these 
results suggested that an IgG1 antibody prevalent in women with PE near delivery 
recognized an N-terminal linear epitope of EBNA-1 from the Epstein-Barr virus.   
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Figure 3-4: IgG subtyping experiments demonstrate only the IgG1 specific secondary 
reagent exhibited signal above background.   
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ii. The EB15 binding antibody cross-reacts with a region of GPR50 
In an effort to identify human protein antigens that could be recognized by these 
epitope specific antibodies, BLASTp was applied to identify a set of candidate human 
antigens that exhibit the highest similarity to the library peptide motif (Table 3-2). 
Table 3-2: Candidate antigen fragments 
ID Protein Organism Sequence 
EB15 EBNA-1 Epstein-Barr Virus RPQKRPSCIGCKGTH 
eFB Protein-Pyridine nucleotide Clostridium sp.:  
GPR50 GPR50 Homo sapiens AVPTPYGCIGCKLPQ 
eFA Iron-Sulfur Protein Salmonella enterica VFINEANCVGCKLCV 
disulfide oxidoreductase CAG:127 
DGDKVKNCIGCKSCS 
hF2 Greb1 Homo sapiens LLGFSGNCVGCGKKG 
hF3 Tesmin Homo sapiens MCSSICKCIGCKNYE 
4 Coiled-coil domain 
containing protein 18 Hom apiens 
FSNKEDRCIGCEANK 
hF5 Zinc finger protein 501 Homo sapiens PYE
hF o s
TGEK CVGCGKSF 
 
Although five 15-mer fragments derived from candidate autoantigens were 
evaluated for antibody binding, only one fragment from an N-terminal region of a G 
protein-coupled receptor, GPR50, exhibited significantly increased binding to 
antibodies present in PE patients compared to HOP (Figure 3-5A).  Furthermore, the 
EB15 peptide efficiently competed with PE antibody binding to the bacterial 
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displayed GPR50 fragment with an IC50 value of ~60-80 pM (Figure 3-5B).  In 
contrast, a negative control peptide (NCP) did not affect antibody binding to the 
bacterial displayed GPR50 fragment (Figure 3-6). 
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To investigate antibody binding to the full-length GPR50, cells expressing GPR50 
were investigated by flow cytometry.  In transiently transfected cells, GPR50 
expression at the cell surface was confirmed using an anti-GPR50 monoclonal 
antibody and flow cytometry (Figure 3-7A). In this system of apparently strong 
GPR50 presence, GPR50 expressing cells exhibited increased binding to antibodies 
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 present in pooled PE plasma compared to that observed with untransfected cells 
(Figure 3-7B).  Furthermore, pre-incubating plasma with EB15 blocked antibody 
binding to the full-length GPR50 protein.  
 
* 
** ** 
† *
****
*
**
*
† 
*
† 
A. 
Figure 3-7: The EB15 epitope inhibits antibody binding to HEK293T cells expressing GPR50. 
(A) The GFP signal confirmed transfection of vector, while the anti-GPR50 monoclonal 
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 The empty vector transfected cells also demonstrated significantly reduced 
antibody binding to the PE pools, similar to the untransfected cells (Figure 3-7C).  In 
contrast, empty vector transfected cells exhibited high variability in antibody binding 
to the HOP pools, but compared to untransfected cells, HOP-associated plasma 
antibodies exhibited increased binding to GPR50 transfected cells.  However, 
importantly, incubation with EB15 did not reduce HOP plasma antibody binding to 
the GPR50 transfected cells, indicating this variably increased activity was mediated 
through different antibody specificities than in the PE pools.  
In addition to transient transfection analysis, an immortalized trophoblast cell line, 
HTR-8/SVneo, was assayed for binding to antibody fractions purified from GPR50+ 
PE and GPR50- HOP pools with or without EB15. First, GPR50 expression on HTR-
8/SVneo cells was confirmed by flow cytometry using a GPR50 specific monoclonal 
antibody compared to dary n ontrol (m C) (Figure 3-8A). The EB15 
peptide significantly red  bindin of  antibodies to HTR-8/SVneo cells to 
levels comparable to HOP-associated antibodies as measured by flow cytometry 
(Figure 3-8B).  Thus, the EB15 epitope specific antibodies present in PE were 
ta. 
 a secon  o ly c S
uced g PE
capable of binding to GPR50 expressed on the cell surface in transfected cells and a 
trophoblast-derived cell line.   
To assess expression of GPR50 in human placentas,192 placental tissue sections 
from PE patients were assayed by immunohistochemistry (IHC). Syncytiotrophoblast 
cells were strongly stained by GPR50 monoclonal antibody, but not by an isotype 
matched control (Figure 3-9). Thus, IHC confirmed the presence of the putative 
autoantigen GPR50 in the placen
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* 
Figure 3-8: HTR-8/SVneo cells express GPR50 and EB15 regulates antibody binding to this
trophoblast model cell line. (A) Cells incubated with the GPR50 specific mo
 
iii. EB15 and GPR50 fragments exhibit increased antibody binding activity in PE 
patients 
The 15-mer fragments exhibited significantly higher binding activity among PE 
patients in a subset of the cohort.  Antibody binding activity to bacterial displayed 
peptides in an expanded set of PE (n=42) and HOP (n=43) further assessed this 
differential activity.  Additionally, 21 nulligravid samples were assayed for binding 
activity.  EB15 and GPR50 fragments demonstrated significantly increased antibody 
binding to PE patients compared to HOP and nulligravid samples (Figure 3-10).  
Interestingly, no significant difference existed between nulligravid antibody binding 
acti
d GPR50.  
 
vity and HOP.  The GPR50 fragment exhibited a lower activity range than EB15 
and reduced HOP antibody binding activity.  Antibody binding activity appeared 
evenly distributed across early- and late-onset PE and adverse outcomes.  These 
results highlighted that the PE condition is associated with significantly increased 
antibody binding activity to EB15 an
noclonal antibody
demonstrated binding above background.  (B) Additionally, EB15 
B.
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reduced PE Ig binding to 
the natively expressed GPR50 in HTR-8/SVneo cells to a similar level as HOP Ig.   - p < 
0.03
EB15 -      -       +      +       -       - 
*
 for U-test, †- p < 0.05 for one-sample t-test compared to 100%.  
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Anti-GPR50 Isotype Control 
FOV1 
FOV2 
FOV3 
 
Figure 3-9: PE placental tissue expresses GPR50.  Using the monoclonal antibody against 
GPR50 resulted in strong staining, with higher signal around syncytiotrophoblasts (arrows). 
This staining pattern was confirmed using three different fields of view (FOV) of the same
tissue section 
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D. Discussion 
Here, a PE-associated IgG1 antibody was identified that binds with high affinity 
to EBV protein EBNA-1 and cross-reacts with human GPR50.  Previous studies have 
suggested a role for antibodies in the pathogenesis of PE.  Most notably, IgG 
autoantibodies that agonize AT1 (AT1-AA) have been shown capable of inducing 
blood pressure elevation,3 complement deposition173 and other hallmarks of PE.  In 
addition to AT -AAs, several other PE-associated antibodies have been reported, 
prothrombin.   We previously employed an unbiased discovery approach to 
investigate whether additional antibody specificities exist (Chapter 2)191 and identify 
their preferred epitope binding specificities.  This approach, using antibody fractions, 
indicated the presence of PE-associated antibodies distinct from AT1-AAs, but did not 
reveal either autoantigens or environmental antigens.  Given this problem, we applied 
a substantially modified discovery method termed Antibody Diagnostics via 
800
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130
0.8
8
80
Nulligravid
 EB15      GPR50
Fo
ld
 F
lu
or
es
ce
nc
e
ov
er
 B
ac
kg
ro
un
d
p < 0.01 
p < 0.03 
p < 0.01 
p < 0.0001 
Figure 3-10: PE patients exhibit significantly increased antibody binding to EB15 and 
GPR50 compared to HOP and nulligravid. p-values represent Mann-Whitney U-test analysis
 Evolution of Peptides (ADEPt),189 which has previously revealed specific 
environmental antigens in an unbiased fashion. The ADEPt method revealed a 
specific epitope within EBNA-1 as a target of t
demonstrated that the same antibody species cro tal GPR50. The 
cross-reactivity of a disease-associated antibody to regions of EBNA-1 and a human 
protein, GPR50, potentially holds further implications for PE pathology.   
Our results provide evidence for a novel case of molecular mimicry, a mechanism 
acetylcholine receptor antibodies have been proposed to associate with herpe  
lycoprotein D.30  Peptides derived from the acetylcholine receptor and 
glycopro 33
44
28
135
193  194 195
he immune response in PE, and 
ss-reacts with placen
proposed for a variety of other diseases.  For example, in myasthenia gravis anti-
s
simplex virus g
tein D inhibited antibody binding to the acetylcholine receptor.   Rheumatic 
fever/carditis patients possess cross-reactive antibodies to streptococcal N-acetyl-βD-
glucosamine and cardiac myosin.   Furthermore, three regions of EBNA-1, one of 
which borders and partially overlaps with our EB15 fragment, bind lupus-associated 
antibodies.   An additional case for molecular mimicry in PE was proposed for the 
generation of AT1-AAs, and a human IgG directed against parvovirus B19 VP2 
demonstrated positivity in the AT1-AA detection assay.   Thus, molecular mimicry 
represents a proposed mechanism of etiology for autoantibody activity in several 
diseases. 
The Epstein-Barr virus (EBV), in spite of being ubiquitous in humans world-
wide, has been associated with a variety of diseases.  For example, EBV reactivation 
is linked to the development of Burkitt’s lymphoma and nasopharyngeal 
carcinoma. Interestingly, 30%  to 36%  of pregnant women show signs of 
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 EBV reactivation based on serum antibody panels.  Furthermore, the placental gene 
expression of the Epstein-Barr virus induced gene 3 (EBI3) appears increased in 
PE.196  EBI3 comprises part of IL-27, which inhibits CD4+CD25+ regulatory T-cell 
development,197 and regulatory T-cell levels are decreased in PE.123,124  Therefore, 
reactivation could result in increased viral activity leading to a myriad of effects, 
including amplified antibody titers in a group of women that possess this antibody 
spe
triglyceride levels,202 and hyperlipidemia often precedes PE presentation.203  
Tak
cificity ultimately leading to aberrant binding activity to human proteins, such as 
GPR50.   
While the function of GPR50 is poorly understood, several observations relate to 
PE pathology.  First, the presence of GPR50 in the model trophoblast cell line, HTR-
8/SVneo cells, agrees with a previous finding of GPR50 presence in the placenta,192 
which we further confirmed.  Second, since the PE-associated antibody represents an 
IgG1 subclass, which activates the complement system, antibody binding to this 
placental GPR50 could contribute to the increased complement deposits observed in 
the PE placenta.119,122,173  Through dimerization, GPR50 inhibits the melatonin 
receptor 1,198 and while melatonin exhibits a protective effect in the placenta199 and 
helps regulate blood pressure,200 the levels of melatonin and melatonin receptors 1 
and 2 are reduced in PE.201  Furthermore, mutations in GPR50 have been linked to 
increased 
en together, these observations suggest that EBV-induced autoantibodies to 
GPR50 may be pathogenic in PE, and future studies should be designed to investigate 
this question.  
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 Our finding that the GPR50 epitope was reactive with the largest number of PE 
specimens does not rule out the possibility that other, less similar human proteins 
might also bind to the EB15 directed antibody.  Although we focused on cross-
reactivity to GPR50 due to its increased binding activity compared to the other 
evaluated fragments, we observed moderate activity in some PE to other candidate 
targets.  Therefore, cross-reactive binding to these and potentially other less similar 
autoantigens may occur.  For example, kininogen-1 appears dysregulated in PE204,205 
and shares the CVGC sequence, potentially leading to low activity binding.  Thus, 
aside from GPR50, other autoantigens could be recognized by this antibody species 
and contribute to the heterogeneity in presentation and severity of PE.   
Bacterial displayed random peptide library screening enabled the impartial 
identification of an EBV directed antibody capable of cross-reacting with a human 
placental protein.  Therefore, this study provides support for an aberrant immune 
response in PE through a mechanism of molecular mimicry involving a viral antigen 
(EBNA-1) and human proteins, especially the placental protein GPR50.  Although 
this study focused on PE, this approach can be extended to a variety of diseases to 
impartially profile disease-associated antibody-antigen interactions.           
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 4. Using next-generation sequencing to characterize individual patient antibody 
binding specificities  
 
Next-generation sequencing (NGS) has significantly increased throughput (>5 
million sequences) compared to traditional Sanger sequencing methods.  Thus, NGS 
enables in depth analysis for a variety of applications, including evaluation of isolated 
sequences from peptide library display screening.  In particular, multiple individual 
screens can be probed simultaneously without excessive numbers of sorting/selection 
rounds to reduce diversity.  We sought to develop and apply a unique method of 
bacterial displayed peptide library screening with NGS to profile individual antibody 
repertoires from pre-eclampsia (PE) patients (n=4) and healthy-outcome pregnancies 
(n=4).  Validating this methodology, we re-identified the previous viral antigen-
linked PE-associated motif (KXXXC[VIL]GC).  An additional PE-enriched motif 
(GXXGAGGG) supports an amplified immune response to the Epstein-Barr virus 
nuclear antigen 1.  This unique approach simultaneously identified PE- and healthy 
pregnancy-associated motifs, highlighting an altered antibody response among 
women with PE. 
A.  Introduction 
The advent of next-generation sequencing (NGS) has enabled high-throughput 
evaluation of millions of sequences, providing a rich source of data.  This tool has 
tremendous potential to change genomics and clinical diagnostics as we quickly 
approach the $1000 personal genome.206  Thus far, current diverse applications of this 
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 technology include evaluation of phage display library panning,207,208 gene mutation 
analysis,209 influenza inhibitor design,210 and DNA aptamer selection.211 The ability 
to sequence >400 billion oligonucleotide bases enables full coverage of T- and B-
cells from small organisms, such as zebrafish.212 Although the full repertoire in 
humans has yet to be completely understood, certain insights have been gained.  
Profiling the antibody repertoire in humans by sequencing circulating B-cells 
provided evidence for B-cell memory recall.   Immune repertoire sequencing has 
revealed alterations in multiple sclerosis,  leukemia,  and severe aplastic 
anemia.   Furthermore, NGS has provided insights into ongoing immune responses 
through specific isolation and sequencing of antibody-producing plasmablasts.   
NGS enables an enhanced understanding of the immune repertoire diversity, and it 
has been used to estimate the naïve T-cell repertoire diversity as 3-4x10  (three to 
four-fold higher than previously expected).   As these studies demonstrate, NGS 
represents an invaluable tool for probing the immune repertoire. 
Given this useful tool, we sought to develop and apply a method to profile 
antibody binding specificities using NGS and bacterial displayed peptide library 
screening.  In previous work, peptide library screening incorporated pools of disease 
and healthy samples and required multiple rounds of sorting to reduce library 
109 to ~1000 members for traditional sequencing (Chapters 2 and 
3).1
53
186 187
188
51,52,213
6
214
diversity from 8x
53,189,191  However, one study demonstrated that the most abundant sequences 
identified after four phage selection rounds were among the most abundant in the 1st 
or 2nd round,  but the high diversity at these rounds prevents identification by 
traditional sequencing (~50 clones).215  Thus, we aimed to characterize antibody 
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 binding peptides isolated from early screening rounds against individual samples at 
higher library diversity (104-105 members).  We hypothesized that this approach 
would greatly reduce the number of sort rounds while providing an in-depth profile of 
the antibody binding repertoire for each individual.  Instead of focusing on the highly 
enriched sequences that bind antibodies present in disease plasma,68,208 a 
computational algorithm developed in the Daugherty Group at UCSB (Pantazes R, 
Reifert J, Elliott SE, et al. 2014, unpublished), compares the disease- and control-
associated sequences.  This algorithm evaluated the presence of enriched patterns of 
amino acid sequences instead of full-length peptides,68,183 which may reduce the 
number of unique contributors when identifying motifs.  Applying this methodology 
to the pregnancy-related disease, pre-eclampsia (PE), confirmed the previously 
characterized viral antigen-linked motif (Chapter 3) and elucidated additional PE- 
and healthy-outcome pregnancy (HOP)-associated motifs.  Our results show that 
NGS-enabled antibody binding motif analysis yields broad insights into disease-
rela
B.  Materials and Methods 
i. Patient samples 
 
ted alterations to the antibody repertoire.   
A heterogeneous set of PE and HOP (n=4, each) were selected from the same 
cohorts previously described (Chapters 2 and 3).  In addition to clinical parameters, 
the samples showed a range of average antibody binding activity to the previously 
identified and tested antigen fragments from Chapter 3 (Table 4-1).       
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Table 4-1: Characteristics of samples for next-generation sequencing analysis 
Average Antibody Max Blood Enzyme 
 Binding Activity  Pressure Proteinuria WGA
Elevated 
Levels  CNS 
ID EB15 GPR50 SBP DBP Y or N wk Y or N Y or N
PE-1 26 5.3 152 99 Y 37.5 Y N 
PE-3 15 6.3 148 102 N 32 N 
HOP-3 31 1.3 111 66 N 38.5 ND N 
PE-2 1.8 1.3 155 90 ND 36 N Y 
Y 
PE-4 1.7 0.89 167 90 Y 36 Y Y 
HOP-1 1.3 0.90 120 55 N 40.1 ND N 
HOP-2 1.5 1.2 134 70 ND 38.6 ND N 
HOP-4 6.2 1.0 98 59 ND 38 ND N 
 
ii. Library screening 
A fully randomized, 15-mer peptide library displayed on eCPX90 was screened 
against diluted plasma from individual PE and HOP.  Samples were diluted (1:50) 
and depleted of E. coli binding antibodies prior to library incubation as previously 
described (Chapter 3).  A magnetic selection step quickly removed irrelevant 
peptides in preparation for fluorescence activ
Average antibody binding of samples from previous studies expressed as fold fluorescence
over background.  Abbreviations: ND – not determined, SBP – systolic blood pressure, DBP, 
system. 
diastolic blood pressure, WGA – Weeks’ gestational age at delivery, CNS – central nervous 
ated cell sorting (FACS).  A biotin-
conjugated anti-human IgG secondary (1:500) (Jackson ImmunoResearch) was used 
to detect bound IgG following incubation with diluted plasma (1:100).  Finally, cells 
were labeled with streptavidin (SA)-conjugated magnetic beads and application of a 
magnet enabled isolation of antibody bound 
(SA-PE) fluorescently labeled the cells expressing peptides bound to antibodies.  
Labeling reagents were diluted in PBS with 0.1% BSA and incubations conducted at 
cells.  Two rounds of FACS further 
enriched the peptide library for each individual sample.  In this case, two 
concentrations of diluted plasma (1:100 and 1:500) were used.  The same biotinylated 
anti-human IgG secondary (1:500) was used, but SA conjugated to R-phycoerythrin 
 4°C.  Sort gates were set according to a similarly treated negative control expressing 
only the dis  f f FACS (F1) collec p 4% of 
bind at 1 las i h on  (F iso e
fluorescing cells from th al b g ulati serv ith a 500 p a 
dilution.  To are t stringency single F S sort e 
population following magnetic selection (PE-1) was sorted against 1:500 diluted 
pl cub  the lib  with on  and E on o pl ) evaluated 
iii. Library preparation for sequencing 
Following library screening, the plasmids were isolated from cells using Zyppy™ 
Plasmid Miniprep kit (Zymo Research).  In addition to the four PE and HOP after two 
rounds of FACS, populations from other sort rounds with PE-1, PE-3, HOP-2, and 
HOP-4 were included for sequencing.  The peptide encoding regions of the plasmid 
were amplified and prepared for sequencing (Figure 4-1) on the Illumina platform, 
MiSeq.  Specifically, a two-step PCR process modified from an existing protocol216 
ensured amplification of the peptide region and addition of the required flanking 
adapter and barcoding sequences.  The initial primers (For1 and Rev1) amplified the 
peptide encoding section of the plasmid while adding annealing regions for the 
second set of primers (Table 4-2).  In the second PCR, primers from the Nextera® XT 
Index Kit (Illumina) added the adapter sequences and barcodes (i5 and i7) for dual-
indexing.  The first PCR underwent 25 cycles while the second used 8 cycles with 
annealing temperatures of 65°C and 62°C, respectively.  This two-step PCR resulted 
in 12 different samples, multiplexed by 12 unique i7 barcodes with the same i5 index.   
play scaffold.  The irst round o ted the to
ers :100 p ma dilut on, t e sec d round 2) lated th  higher 
e tot indin  pop on ob ed w  1: lasm
comp his strategy to a higher AC , on
asma.  In ating rary  sec dary  SA-P ly (n asma
the presence of false-positives binding to secondary or SA alone.      
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The 12 unique samples were pooled together in equal amounts following 
quantification by Qbit, using an estimated length of 214 bases and Equation 4.1.  
After diluting each sample to 4 nM, 5 µL of each was removed and pooled together. 
An Agilent Bioanalyzer run evaluated the size and purity of the final pool. 
 
 
(4.1)          (nM)ion concentrat10L)(ng/ion concentrat 6 =×
bp 200  (g/mol) 660 ×
μ  
 
library screening, peptide encoding regions are amplified and modified to include adapte
Figure 4-1: Library screening and preparation for next-generation sequencing.  After initial 
r 
 
s 
sequences, barcodes, and sections required for sequencing.  Finally by de-multiplexing and
comparing the individual PE and HOP we can identify unique peptide sequences and pattern
among PE. 
 Table 4-2: Primers used for library preparation 
Primer Sequence 
For1: TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGGCCAGTCTGGCCAG 
Rev1: GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGCTGCCACCAGAACCGCC
 
iv. Motif characterization 
A computational algorithm, termed Identifying Motifs Using Next-generation 
sequencing Experiments (IMUNE), developed in the Daugherty Group at UCSB 
(Pantazes R, Reifert J, Elliott SE, et al. 2014, unpublished) was applied to the de-
multiplexed samples to identify patterns of amino acids significantly enriched in the 
PE samples compared to the HOPs.  Different enrichment conditions were evaluated 
across the 8 samples. These conditions include: 4_0, 4_1, 3_0, 3_1, 2_0, and 2_1, 
indicating the number of PE and HOP, respectively, with a given statistically enriched 
pattern.  Related patterns identified with these different enrichment conditions were 
combined to identify common motifs.  A Python code (MotifSearcher) enabled 
searches for sequences comprising a specific motif from the list of unique peptides to 
r of sequences containing the searched motif.  Specifically, if a given 
pep
employed.  
Comparing sequence observations after two FACS rounds (F2) to those in the first 
round (F1) identified the enriched sequences, or those representing a higher fraction 
Shaded region represents the complementary sequence for annealing to the desired regions
of the plasmid for peptide encoding section amplification.   
generate a traditional sequence logo.  This analysis determined the number of 
peptides significantly (≥95% of observations) associated with PE samples out of the 
total numbe
tide sequence was observed 19 out of 20 times in one of the four PE patients, it 
was considered PE-associated.  At the same time, the control- or HOP-specific motifs 
were similarly characterized. 
For additional motif analysis, the web-based MEME algorithm98 was 
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 of the total sequences in F2 than F1.  Cases in which a sequence appeared >10 times 
u ere 
algorithm characterized five motifs from the top 1000 ranked sequences.  To
characterize the effect of sort stringency, the single FACS round against PE-1 with 
1:500 diluted plasm
tic selection reduced the library population diversity 
fro
in F2 b t never observed in F1 were also included.  These enriched sequences w
ranked according to the number of observations in the F2 population.  The MEME 
 
a was compared to the population that underwent a less stringent 
F1 (1:100 dilution) followed by a second sort with 1:500 diluted plasma.   
v. Candidate antigen identification 
To relate generated motifs to candidate antigens containing the same amino acid 
sequence, a variety of search algorithms were employed.  Primarily, NCBI BLASTp 
and ScanProsite determined the proteins with similarities/identities to variations of 
motifs.  Additionally, the Immune Epitope Database was searched for sequences with 
positive antibody binding activity.  Where appropriate, hits from organisms, such as 
western clawed frog, fruit fly, or extreme thermophiles, that would be rarely involved 
in the human immune system were removed from search results.  Additionally, 
uncharacterized or putative protein hits were not included.   
C. Results 
i. Screening peptide display library for patient-specific binders 
The first round of magne
m 8x109 to ~106 members.  This reduced diversity enabled FACS-based sorting for 
the subsequent rounds.  The different PE and HOP samples enriched for binders at 
different rates (Figures 4-2 and 4-3).    Only one sample (PE-2) exhibited less than 
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 75% binding after two rounds of FACS (F1 and F2) at 63.4% binding, despite 
exhibiting the highest percent binding after the initial magnetic selection.  
Interestingly, library screening against PE-1 and PE-3 enriched for the highest percent 
binding out of the four PE samples and these samples previously showed increased 
binding to antigen fragments EB15 and GPR50.  Additionally, peptide library 
screening with HOP-3, which showed the highest antibody binding activity against 
EB15, enriched the fastest.  For the other samples, less than 30% of the population 
bound to sample antibodies after one round of FACS; however, HOP-3 exhibited 
73.5% binding.  Comparatively, the stringent F1 sort against PE-1 (1:500), resulted in 
a higher percentage (56%) of binders post F1 than when sorted using a 1:100 dilution 
(21.5%).  This indicated that increased stringency enhanced enrichment of strong 
binders; however, both populations exhibited a bimodal distribution of binding 
peptides. 
Importantly, the majority of peptide sequences in each library population 
following two FACS rounds bound to the specific sample being screened against, 
reducing the background noise of nonbinding peptides during sequence analysis.  The 
lack of streptavidin binders was also confirmed.  Estimated diversities of ~104 
abled pooling of the individual screens for multiplexed sequencing by 
MiSeq.  After separate PCR amplification using a two-step process, the DNA 
concentration of each pool was measured to facilitate equimolar pooling.  The Agilent 
Bioanalyzer confirmed the correct size and purity of the pooled DNA.  
members en
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Figure 4-2: Individual screens enriched the library against different PE samples. Each distinct 
screen resulted in a majority population of cells expressing peptides that bind to unique PE.   
  98
MCF: 534
Bind: 9.5%
MCF: 3006
Bind: 85.9%
MCF: 242
Bind: 7.5%
HOP-1
Post M1
1:100
Si
de
 S
ca
tte
r
HOP-2
HOP-3
HOP-4
MCF: 1182
Bind: 22.5%
MCF: 1868
Bind: 82.5%
MCF: 278
Bind: 4.4%
Si
de
 S
ca
tte
r
MCF: 737
Bind: 6.7%
MCF: 4742
Bind: 73.5%
MCF: 3623
Bind: 86.1%
Si
de
 S
ca
tte
r
MCF: 245
Bind: 4.4%
MCF: 743
Bind: 28.6%
MCF: 1455
Bind: 86.1%
Red Fluorescence
Si
de
 S
ca
tte
r
Post F1
1:500
Post F2
1:500
 
 HOP. 
ii. Sequence analysis identifies the viral antigen-linked motif among other PE-
associated motifs 
From MiSeq sequencing, a total of ~7x106 usable reads were identified.  The 
redundant set of peptides was normalized to ~7.3x105 unique sequences across all 
twelve samples.  The sequence counts for individual screens varied (Table 4-3).     
Despite the reduced number of total usable reads in the post F1 populations, these all 
Figure 4-3: Individual screens enriched the library against different HOP samples. Each 
distinct screen resulted in a majority population of cells expressing peptides that bind to uniq  ue
 exhibited higher unique sequences than the corresponding post F2 populations.  This 
reflects the higher diversity among the post F1 populations.  Due to the reduced 
coverage (fold oversample), a significant portion (~40-70%) of sequences from post 
F2 was not observed in the post F1 populations. 
Table 4-3: Number of sequence reads for each sample 
Sample ID Unique Total Fold Oversample 
PE-1: Post F2 48,464 337,992 6.97 
PE-2: Post F2 77,657 715,905 9.22 
PE-3: Post F2 29,434 1,046,613 35.6 
PE-4: Post F2 40,877 171,159 4.19 
HOP-1: Post F2 34,900 658,011 18.9 
HOP-2: Post F2 136,517 677,586 4.96 
HOP-3: Post F2 69,488 466,980 6.72 
HOP-4:Post F2 61,179 942,076 15.4 
PE-1: Post F1 (1:500) 58,474 222,265 3.8 
PE-3: Post F1 62,390 257,594 4.13 
HOP-2: Post F1 177,324 510,591 2.88 
HOP-4: Post F1 105,199 191,298 1.82 
Applying the IMUNE algorithm identified a redundant list of statistically enriched 
patterns for a variety of comparisons.  In these patterns, an X indicated that no amino 
acid was significantly enriched at that position.  Combining similar patterns led to a 
general motif for different sets of patterns.  Observed in different enrichment 
conditions, one dominating pattern set (>50 unique patterns) contained the previously
(Fi otif 
ally identified using sequential enrichment and depletion of plasma 
poo
 
identified viral antigen (EBNA-1)-linked motif from Chapter 3, KXXXC[VLI]GCK 
gure 4-4).  Aligning these enriched patterns resulted in a general binding m
similar to that initi
ls (Chapter 3).  Based upon this pattern alignment, a search of KXXXCXGC in 
the list of unique sequences yielded the full set of 15 amino acid peptides containing 
motif 1.  A majority of these peptides (80%) was identified as significantly associated 
with PE samples and used to generate a sequence logo.  Although left undefined 
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 during the search, amino acids valine, isoleucine, and leucine showed increased 
representation in the middle position, similar to the first generation motif previously 
identified (Figure 3-2).  Also similar to this first generation motif is the lack of a C-
terminal lysine that showed enrichment after directed evolution (Chapter 3). 
 
In evaluating the other highly represented patterns, another set was identified as 
enriched in three PE and only one HOP.  Evaluating the similarities from these ~35 
patterns elucidated a second PE-associated motif ([LME][YW]X[WFY]DX[RK])  for 
searching the unique sequence list (Figure 4-5).  Interestingly, this shared some 
similarities with motif c, WGWGXX[RK], identified in a previous antibody profiling 
study using antibody fractions (Chapter 2).191   
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Figure 4-4: Identifying the PE-associated peptides containing the viral antigen-linked motif. 
Several patterns observed to be significantly enriched in PE patients screened represented 
the previously identified motif.  After searching the unique peptides for this motif, the number
PE-
Associated
Total  
of PE-associated peptides were identified and aligned to generate a sequence logo.   
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Motif 1 comprised four fixed residues, while motif 2 shared five positions but 
only one was com
 
of PE-associated peptides (91%).  This aligned with the observation that thes
pletely fixed.  Despite the increased number of unique sequences 
containing motif 2 (1683) than motif 1 (1465), motif 2 exhibited a higher percentage
e 
sequences predominantly stemmed from 3_1 enriched patterns.  Additionally, since 
two of the HOP samples used in this analysis possessed antibodies capable of binding 
to EB15, these contribute to the reduced percentage of PE-associated peptides 
observed in motif 1 compared to motif 2.   
Figure 4-5: Characterizing a new PE-associated motif.  Similar patterns found to be 
statistically enriched in three PE were combined to characterize the motif.  Searching the set 
of unique peptides identified the PE-enriched sequences for logo generation and determined
the number of PE-associated peptides.
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 Another motif initially consisted of three defined positions (GAG).  Almost 
25,000 sequences posse ese occurred ≥95% of the 
time in PE samples.  However, using the generated sequence logo (Figure 4-6A) to 
define additional residues (GXXGAGGG) er peptides but 
these exhibited a higher enrichment among PE patients (Figure 4-6B).  Thus, motif 3 
consisted of 723 disease-enriched sequences out of 793 total (91%).  This highlighted 
the importance of refining motifs to understand PE-associated epitopes. 
 
tified enriched patterns. In fact, one motif 
(ASXTXW) consisted of more HOP-associated peptides. 
entified many sequences; however, a substantial
percenta
the
ssed this motif, but only 75% of th
, the search returned few
Search: GAG A. B. Search: GXXGAGGG 
The motifs identified by patterns significantly enriched among PE samples 
according to the IMUNE algorithm exhibited a high percentage of disease-associated 
unique peptides.  For comparison, a number of patterns identified by the algorithm 
from the 2_1 comparisons with reduced enrichment in PE compared to HOP were 
evaluated for PE-associated peptides.   The patterns with low enrichment according to 
IMUNE exhibited similar numbers of disease and control peptides (Figure 4-7), 
indicating the significance of IMUNE-iden
ge of these were not enriched in PE.  (B) Using six defined positions decreased
 total sequence count to ~800, but 91% of these were highly enriched in PE. 
Figure 4-6: Defining additional motif positions increases PE-associated enrichment.  (A) 
Using only three defined positions id
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. Candid rmined from eas
Focusing on the most represented amino acids as indicated by the sequence logo 
(L[YW]XWDXR) resulted in reduced total sequences (720) but increased specificity 
(93%).  Searching this motif in ScanProsite identified a number of interesting 
candidate antigen hits.  Initially searching the human proteome returned five unique 
protein hits (Table 4-4).  Among nonhuman hits, several represent homologues to 
t  
(  
path
iii ate antigens dete dis e-associated motifs 
hese human proteins in mice and rats.  Interestingly, a prominent reoccurring hit
~580 strains) represented a protein from Acinetobacter baumannii, an opportunistic
ogen associated with hospital-derived infection.    
 Table 4-4: Human protein hits for prominent next-generation 
sequencing motif L[YW]XWDXR 
Human Protein Sequence 
Calmodulin-binding transcription activator 1 AAVVLYKWDRRAISI 
Protein cordon-bleu.  GIKELYAWDNRRETF 
Elongation factor G, mitochondrial FLPLLWNWDRRSGSQ 
Insulin-like growth factor 1 receptor. NLQQLWDWDHRNLTI 
Prostaglandin F2-alpha receptor Isoform 5 LQMRLWTWDFRVNAL 
Motif 3 (GXXGAGGG) corresponded to a common sequence found in a variety 
of viruses and pathogens, including the human adenovirus, Epstein-Barr virus (EBV), 
and torque teno virus.  Searching the Immune Epitope Database returned 36 positive 
DXRXXEXR ASXTXW GXXMWD AXXXXWXXR
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 hits for antibody-antigen binding.  Many of these hits represented the same organism 
or multiple studies identifying similar sequences.  Thus, these hits were condensed to 
six unique organisms, including EBV and a section of EBNA-1 that represents the 
immunodominant region217 (Table 4-5).  Although this motif may be present among 
the HOP samples it appeared significantly enriched among these PE.   
These IMUNE-identified PE-enriched motifs enabled candidate human and 
pro [VIL]GC and 
GX
environmental antigen discovery.  Importantly, this in-depth antibody repertoire 
filing approach distinguished two distinct motifs (KXXXC
XGAGGG) from the same viral antigen, EBNA-1.  This discovery highlights an 
altered antibody response to this antigen among PE patients. 
Table 4-5: Positive antibody binding hits in the Immune Epitope Database 
for motif GXXGAGGG 
Sequence Protein Organism 
GAGGGAGAGGAGAGGGGRGR Epstein-Barr nuclear  Human  
GAGGGAGGAGAGGGAGGAGA antigen 1 (EBNA-1) herpesvirus 4 
AGGAGAGGGAGAGGA   
SSSSAGGGGGGAGGGGGGGG early phosphoprotein P34 herpesvirus 4 
Human 
MTSVNSAEASTGAGGGGSNSVK 
Probable coat protein Human 
VP1 parvovirus B19 
TGAGGGGSNSVKSMWSEGATFS VP2 
Human 
parvovirus B19 
SGGGAGGGSSGSGQSGVDLSPV 
Adhesin P1 precursor 
(Cytadhesin P1) Mycoplasma 
(Attachment protein) pneumoniae 
LKE r unataSGVKPGQFAAIVGAGGGL alcohol dehyd ogenase Curvularia l
GLS G LSAPSTGAGGGLPGP Myelin basic protein Cavia porcellus 
LGG
artite motif
ining 67 ns GAGGGGDHADKLSLYSETDS conta
trip -
Homo sapie 
iv. Identifying control-specific motifs and related candidate antigens 
In addition to discovery of PE-associated motifs, this methodology of individual 
screening followed by cross-examination of PE- and HOP-enriched patterns, enabled 
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 identification of control- or HOP-specific motifs.  To focus on truly HOP-specific 
motifs, the patterns enriched in four HOP and zero or one PE samples were evaluated.  
This analysis led to three main motifs identified as highly enriched among HOP 
samples (Figure 4-8 A-C).  The HOP-specific sequences comprising these motifs 
represented 95.7%, 97.7%, and 92.9%, respectively, of total sequences. These 
control-associated specificities may be present among PE but reduced compared to 
the PE-associated motifs identified.  Control-specific motifs highlighted a skewed 
antibody repertoire among the PE samples.    
[PGA]H[DE][WY]K[GA][ST][ST]GX[KR]
A. B.
YX[TSA][TS]LX[YW]C.
 
Fig ) One motiure 4-8: Control-specific motifs identified using the IMUNE algorithm.  (A f
 
One motif (Figure 4-8A) comprised more sequences than the others; however, it 
mainly consisted of the highly represented amino acids glycine and serine.  Therefore, 
 
com eprised the largest number of sequences; however, (B) (C) other motifs exhibited high r 
sequence complexity.  All motifs exhibited high specificity (>92%) for control samples. 
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 searches of the protein database using BLASTp did not return any significant hits and 
ScanProsite identified greater than 900 hits.  For the other two motifs, the set of 
protein hits and corresponding organisms were evaluated and summarized.   The 
control motif [PGA]HD[WY]K exhibited the greatest sequence complexity and 
resulted in the fewest hits (Table 4-6).  Many of these hits include pathogenic viruses, 
such as human cytomegalovirus, or commonly encountered organisms like 
Saccharomyces cerevisiae.  No human protein hits were identified for this motif using 
ScanProsite.  In contrast, motif YX[TSA][TS]LX[WY] resulted in a large variety of 
hits, including several human proteins (Table 4-7) and various pathogens (Table 4-
8).  For some of these human hits, homologous proteins were identified in other 
organisms, such as primates, horses, rabbits, and mice.   
Table 4-6: Candidate antigens for HOP-specific motif [PGA]HD[WY]K 
Sequence Protein Organism 
PHDYK Cellobiose 2-epimerase Ruminococcus albus 
AHDYK D-alanine--D-alanine ligase Clostridium novyi 
PHDWK Envelope glycoprotein H Human cytomegalovirus 
AHDYK Glycerol kinase  Francisella philomiragia 
PHDYK Hyaluronan synthase Streptococcus pyogenes  
AHDYK Apolipoprotein N-acyltransferase Salmonella typhimurium 
PHDWK Protein LST4 Kluyveromyces lactis 
AHDYK Nucleotide exchange factor SIL1  
GHDYK Ribonuclease alpha-sarcin Aspergillus giganteus 
AHDYK Ribonuclease H Saccharomyces cerevisiae 
GHDWK Exosome complex exonuclease DIS3  
AHDYK Nucleotide exchange factor SIL1  
GHDYK Ribonuclease mitogillin Neosartorya fumigata 
GHDYK Ribonuclease mitogillin Aspergillus restrictus 
AHDYK Ubiquitin-like protein-NEDD8-like 
protein RUB3 
Oryza sativa subsp. japonica 
AHDYK ATP-dependent RNA helicase SrmB Haemophilus influenzae 
AHDYK TonB-dependent heme receptor A Haemophilus ducreyi 
GHDYK UvrABC system protein B Ureaplasma parvum serovar 3 
AHDWK Glycoprotein G Rabies virus 
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 Table 4-7: Candidate antigens from the human proteome for HOP-specific motif 
Sequence Protein 
YX[TSA]TLX[WY] 
YISTLPY A-kinase anchor protein 1, mitochondrial 
YNSTLTW Wolframin 
YIATLLY Myelin and lymphocyte protein 
YLSTLRW Cystic fibrosis transmembrane conductance regulator. 
YFSTLDY Cation channel sperm-associated protein 3 
YLATLTW EGF-like module-containing mucin-like hormone receptor-like 2 
YKSTLGY DnaJ homolog subfamily C member 18 
YTTTLDY Protein FAM101B 
YLTTLAW Olfactory receptor 5A1 
YLSTLLY Bardet-Biedl syndrome 12 protein 
YSSTLRW UPF0378 protein KIAA0100 
YQSTLPW Sushi domain-containing protein 5 
YASTLGY Transcription factor SOX-14 
YLSTLYY Sushi, von Willebrand factor type A, EGF and pentraxin domain-
containing protein 1 
YVATLDY Protein transport protein Sec24D 
YVTTLLY 5'-AMP-activated protein kinase subunit beta-1 
 
Table 4-8: Candidate environmental antigens for HOP-specific motif 
  
YX[TSA]TLX[WY] 
Sequence Protein Organism
YVATLVY Dol-P-Glc:Glc(2)Man(9)GlcNAc(2)-PP-
Dol alpha-1,2-glucosyltransferase 
Emericella nidulans 
Y
ibonuclease subunit B 
. 
ereus, 
ETTLTY ATP-dependent 
helicase/deoxyr
Bacillus thuringiensis, B
weihenstephanensis, B. c
B. anthracis 
YGATLRY Protein FimA Bordetella pertussis 
Y ipin synthase ClsA WATLSY Major cardiol Bacillus subtilis 
YNTTLKY Envelope glycoprotein B Human cytomegalovirus 
Y HKU1 LSTLWY Spike glycoprotein Human coronavirus 
YKTTLEY Mitochondrial Rho GTPase 1 Candida albicans 
Y Schizosaccharomyces pombe KTTLAY Mitochondrial Rho GTPase 1 
Y 3  SSTLLY Secretory component protein psh
YRATLNW Glutamyl-Q tRNA(Asp) synthetase Yersinia pestis, Y. 
pseudotuberculosis 
YMSTLTY Alpha-hemolysin Staphylococcus aureus 
YFSTLNY Vacuolar ATPase assembly integral 
membrane protein VMA21 
Cryptococcus neoformans 
Y visiae GSSLQW A1 cistron-splicing factor AAR2 Saccharomyces cere
YTTTLTY Cell wall protein AWA1  
Y ridine(16/17) synthase 
[NAD(P)(+)]  
  
GATLAY tRNA-dihydrou  
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 Table 4-8:  Continued  
Sequence Sequence Sequence 
YTTTLTY Haze protective factor 1 Saccharomyces cerevisiae 
YRSTLNY Cysteine-tRNA ligase 1 Tropheryma whipplei 
YESTLNY PAB-dependent poly(A)-specific Scheffersomyces stipitis 
ribonuclease subunit PAN2 
YFTTLTY Tetraacyldisaccharide 4'-kinase Bacteroides vulgatus 
YEATLAY Isopentenyl-diphosphate delta-isomerase Lactobacillus casei 
YTSTLNW Cellulose synthase catalytic subunit Escherichia coli 
YETTLAW Cellulose synthase catalytic subunit 
[UDP-forming] 
Xanthomonas axonopodis 
YVSTLLY TP-dependent dethiobiotin synthetase 
BioD 
Fusobacterium nucleatum 
YQTTLSY Vitamin B12 transporter BtuB Vibrio vulnificus 
YLSTLFY CD2 homolog African swine fever virus 
YGSTLDW UPF0061 protein YdiU Salmonella enteritidis PT4 
YTSTLNW Cellulose synthase catalytic subunit 
[UDP-forming] 
Salmonella typhimurium 
YQATLDY Adenylosuccinate synthetase Serratia proteamaculans 
YDSTLSY  FO synthase Mycobacterium tuberculosis, 
M. bovis, M. leprae, M. 
paratuberculosis 
YPSTLGY Methionin Me aminopeptidase 2 ycobacterium tuberculosis, 
M. bovis 
YPATLEY Queuine tRNA-ribosyltransferase Haemophilus ducreyi 
YFSTLYY L-rhamnonate dehydratase Burkholderia ambifaria, B. 
s, B. phymatum, B.  phytofirman
xenovorans 
YVTTLTY DNA-directed RNA polymerase subunit 
beta 
Arcobacter butzleri 
YDSTLDY  FO synthase Nocardia farcinica 
YSSTLDY FO synthase subunit 1 Methanosarcina acetivorans 
YSSTLEY FO synthase subunit 1 Methanosarcina barkeri, M. 
mazei 
YPSTLRY Xylanolytic transcriptional activator 
xlnR 
Aspergillus terreus 
YGSTLVY Endo-1,4-beta-xylanase A  Butyrivibrio fibrisolvens 
YYSTLLY Protein transport protein SEC23 iculi Encephalitozoon cun
YLSTLYY L-rhamnonate dehydratase Delftia acidovorans 
YLTTLEY RNA-directed RNA polymerase L Newcastle disease virus 
YGSTLSW Probable glutathione S-transferase 
GSTF2 
Oryza sativa subsp. Japonica 
(rice) 
YNTTLLY Bifunctional lycopene cyclase/phytoene haeosphaeria nodorum 
synthase 
P
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 v. Enriched sequences from different sorting rounds with the same sample 
nt tool t, the 
list generated by NGS.  Therefore, only 
rt ro ed to a single 
stringent sor rst FACS screen (F1) (PE-3, HOP-2, and HOP-4) were 
evaluated by MEME.  Analysis of the two PE sample comparisons (PE-1 and PE-3) 
f motifs already identifie ithm 
E-1 inked 
creening ( UNE 
algorithm (Figure 4-4).  The less stringently sorted population indicated a strong 
onstrating
 Furthe entified 
by MEME among the F2 enriched sequences for P
ept for the 
otif did not appear among enriched sequences 
ntributed fewer se
m 
3 (KGXGG[A o the 
G motif (Figu
reflected IMUNE-identified motifs 
Although MEME represents an excelle  for motif developmen
algorithm cannot handle the entire sequence 
the top 1000 sequences enriched in the second so und (F2) compar
t (PE-1) or the fi
demonstrated enrichment o d using the IMUNE algor
(Figure 4-9).  The F2 enriched sequences from P  comprised the EBNA-1 l
motif previously identified by ADEPt s Chapter 3) and the IM
enrichment for PE-associated motifs, dem  that sort stringency affected 
isolation of important disease-related peptides. rmore, the first motif id
E-3 represented another major 
IMUNE-identified PE-associated motif (L[YW]XWDXR) (Figure 4-5) exc
C-terminal arginine.  In contrast, this m
for PE-1.  However, this sample co quences to the motif than PE-2 
and PE-3.  Additionally, two clearly related motifs (XGAG and HXXXGAG) fro
the PE-1 analysis and a motif from PE- G]Q) shared similarities t
predominant PE-associated GXXGAGG re 4-6B).   
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Similar to the disease-associated motifs, the algorithm-identified control-specific 
motifs were represented among the F2 enriched sequences from the HOP samples 
(Figure 4-10). The first motifs from HOP-2 ([RK]AXHEX) and HOP-4 
Figure 4-9: Enriched motifs after two rounds of FACS for PE samples.  (A) Evaluating 
enrichment in PE-1 post F2 versus PE-1 post F1 with stringent sort conditions and (B) the 
PE-3 
p-value
A.
 
(XXHD[WFY]K) appeared related and shared similarities with the [PGA]HD[WY]K 
motif (Figure 4-8B).  Additionally, the third motif ([GA][ST]SGXK) from the HOP-
2 analysis was near identical to the HOP-specific motif comprised of the largest 
B.
post F2 population compared to the F1 population yielded PE-enriched motifs.   
 number of sequences ([GA][ST]SGXK) (Figure 4-8A).  The second motif 
(Y[DSN]T[SA]PR) from the HOP-4 analysis exhibited weak similarities to the third 
algorithm-identified control motif (YX[STA]TLX[WY]) (Figure 4-8C).       
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This comparison analysis between two rounds of sorting the same sample did not 
take into account disease- versus control-associated motifs.  Therefore, some of the 
different motifs identified may be ubiquitously represented and enriched across PE 
Figure 4-10: Enriched motifs after two rounds of FACS for HOP samples.  Direct 
comparisons of peptide observations were made between the second round and the first
round of FACS for (A) HOP-2 and (B) HOP-4.   
 111
 and HOP.  This explains the presence of certain motifs among enriched sequences 
(e.g., EXNRL, WD[NDS]VXK, [ST]NTXK) that did not appear as highly PE- or 
HOP-enriched when using IMUNE.  However, these results demonstrated that 
multiple approaches revealed similar motifs enriched in PE and HOP samples. 
D. Discussion 
In this study, we demonstrated that NGS enables in-depth characterization of an 
individual’s antibody binding repertoire. Specifically, we profiled the binding 
specificities of the circulating antibody repertoire in PE and HOP samples.  By 
identifying PE- and HOP-associated motifs, we provide further evidence of an altered 
immune response among PE patients.  Importantly, in this analysis, we re-identified 
the viral antigen (EBNA-1)-linked motif from previous work (Chapter 3).  This 
serves to co-validate the reproducibility of this motif using a different method and the 
ability of the IMUNE algorithm to identify disease-associated motifs.   
We applied multiple methodologies to characterize differences in antibody 
binding specificities between PE and HOP individuals.  Other similar studies have 
focused on the most repeated sequences identified in the library population.208 
However, different conditions unrelated to binding could account for increased 
representation among library members.  For example, it has been shown that the 
amplification process between selection rounds with phage greatly reduces the 
 
peptides to one for generating the statistical
diversity.207  Instead, for IMUNE, we normalized all observations of the specific
ly enriched patterns, which prevents any 
inappropriately higher sequence repeats from skewing the motifs due to undesired 
issues, such as PCR bias or improved cell growth/expression.  We hypothesized that a 
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 given sequence need only be considered once, since numerous unique peptide 
sequences should comprise important motifs.  A similar extension of this was applied 
to identify human-derived peptides associated with disease from a phage displayed 
library.183  To characterize the enriched peptides, we compared two rounds of sorting 
from the same patient sample.  Thus, the inherent biases, such as cell growth and 
PCR, should be present in both rounds, accounting for these undesired issues.  
Evaluating enriched sequences between a second and third round identified low 
nanomolar affinity binders from a DNA aptamer library. Similarly, the most highly 
enriched peptides corresponded to the motifs identified from the IMUNE algorithm, 
highlighting the skewed antibody response.     
While we re-identified the previous EBNA-1 linked motif (KXXXC[IVL]GCK) 
(Chapter 3), we also discovered further differences between the antibody repertoires 
present in PE and HOP individuals.  One of these motifs (GXXGAGGG) represents a 
previously identified immunodominant region of EBNA-1.   This provides further 
support for an increased antibody response towards this viral antigen among PE 
patients compared to HOP (Chapter 3).  Moreover, the previously described methods 
that depleted peptides binding to HOP-associated antibodies (Chapters 2 and 3) 
would hinder identification of this motif due to the likely presence of this specificity 
among HOP.  This motif was also identified in a region of capsid proteins from 
parvovirus B19, which was previously implicated in PE for a possible molecular 
mimicry mechanism leading to the agonistic antibodies against the angiotensin II type 
1 receptor (AT1-AAs).   Another strong, PE-associated motif (L[YW]XWDXR) 
shared similarities with a number of human proteins, including insulin-like growth 
211  
217
135
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 factor receptor 1 and prostaglandin FP2α receptor.  Interestingly, the insulin-like 
growth factor system appears to play a role in fetal growth, while alterations are 
associated with growth restriction218 and PE patients exhibit reduced levels of 
insulin-like growth factor.219  Additionally, evidence suggests the prostaglandin FP2α 
receptor is expressed in the umbilical vein and potentially mediates the contraction 
effect through the agonist, prostaglandin FP2α.220  Umbilical endothelial cells 
produce increased prostaglandin FP2α when exposed to plasma from women with PE 
compared to healthy pregnancies.221  Effectively linking the candidate autoantigen(s) 
to this motif will require further investigation of antibody binding activity, as shown 
in Chapter 3.  However, the additional PE-associated motifs identified through this 
new methodology enhance our understanding of the altered antibody response in PE 
patients. 
To complement the PE-associated motifs, the discovery of HOP-associated motifs 
provides additional evidence of an altered immune response.  These motifs exhibit 
similarities with a variety of viruses and human pathogens.  Interestingly, several hits 
with the YX[TSA][TS]LX[WY] motif included protein homologs (e.g., 
mitochondrial Rho GTPase 1 and FO synthase) found in different organisms, 
potentially indicating a ubiquitous specificity.  The large diversity of candidate hits, 
especially for the YX[TSA][TS]LX[WY] motif, highlights the need for directed 
evolution (Chapter 3) to expand the motifs and reduce the number of similar 
proteins.  While these antibody specificities may still be present among PE patients, 
their presence appears reduced with respect to the HOP samples or relevant disease-
associated motifs.  A significant reduction in antibody binding activity to these HOP-
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 associated peptides accompanied by increased binding to PE-associated peptides 
could yield an accurate diagnostic.  A previous study included a panel of serum 
peptides with increased and decreased levels in PE compared to HOP that exhibited 
strong diagnostic accuracy.205 Furthermore, understanding the relevant antigens these 
PE and HOP-associated motifs represent may reveal a pathological role for these 
alterations to the antibody repertoire.   
Our results demonstrate the utility of NGS to characterize antibody binding 
peptides isolated by bacterial display library screening; however, this study evaluated 
a small set of samples.  As with many diseases, PE presentation is very heterogeneous 
and the existence of multiple disease subtypes has been proposed.106  Thus, additional 
samples would provide a more accurate representation of disease diversity and enable 
antibody repertoire profiling for various subtypes (i.e., early-onset, nonproteinuric, 
etc.).  Furthermore, supplemental analysis of enriched peptides between sort rounds, 
such as post F1 compared to single magnetic selection, may indicate the point at 
which the sharpest enrichment occurs.  However, especially important for this 
analysis, a higher degree of oversampling of unique sequences must be achieved to 
guarantee complete sequence coverage.  Despite these potential areas of 
improvement, the in-depth antibody binding profile obtained through NGS identified 
PE- and HOP-associated motifs, providing further insights into the altered antibody 
response in PE.  
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 5. Additional applications of the newly developed AT1 epitope binding assay for 
antibody detection 
 
While agonistic antibodies against the angiotensin II type 1 receptor appear to 
play a role in pre-eclampsia pathology, characterizing the presence of these antibodies 
has been limited by assay throughput.  However, we recently developed a high-
avidity assay that enabled higher-throughput fluorescence-based detection of antibody 
binding to the AT  epitope.  Here, we demonstrate extensions of this epitope specific 
binding assay to evaluate antibody presence in non-pregnant women and a new pre-
eclampsia mouse model. 
binding to the epitope characterized for these AT1-AAs.  This assay 
enables higher-throughput analysis for the presence of AT1 epitope binding 
antibodies.  In comparison, recently developed ELISAs using AT1 expressing cells222 
or the second extracellular loop178 do not indicate the specific binding sequence 
1
A. Introduction 
Pre-eclampsia (PE) is associated with an intensified inflammatory condition190 
and increased autoantibody activity,128-130 including antibodies that bind GPR50 
(Chapter 3).  Additionally, agonistic antibodies against the angiotensin II type 1 
receptor (AT1-AAs) appear to play a role in PE pathology.3  However, detecting these 
antibodies remains difficult, since complex, biologic function based assays such as 
cardiomyocyte beat rate2 and luciferase reporter signal,138 show the greatest 
sensitivity. As previously discussed (Chapter 2),191 we developed a novel assay to 
detect antibodies 
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 responsible for the signal.  This is especially important for discerning the PE-
associated AFHYESQ binding antibodies from distinct AT1 receptor binding 
antibody specificities found in other diseases, such as renal allograft rejection.174  
We sought to extend the applications of this assay to determine the presence of 
AT1-AAs in women who have never been pregnant (nulligravid) and a new mouse 
model of PE.  It has been previously shown that non-pregnant normotensive samples 
exhibit reduced levels of AT1 receptor binding antibodies compared to HOP, while 
PE samples demonstrate further increased activity.   Thus, we aimed to further 
characterize this relationship using the epitope specific assay.  Furthermore, recently 
it was shown that injecting pregnant and non-pregnant mice with LIGHT, or tumor 
necrosis factor superfamily member 14, induced symptoms of PE.223  LIGHT is a 
 cytokine that has been associated with autoimmune and 
infl
The previously described AT1 epitope binding assay (Chapter 2)  was applied 
in this study.  A fragment of the characterized AT1 epitope (AFHYESQ) flanked by 
glycine residues to increase flexibility was displayed on bacteria using the eCPX 
178
pro-inflammatory
ammatory conditions.224  The results of this study and others190 provide support 
for an intensified inflammatory condition associated with PE.  Thus, we sought to 
evaluate the presence of AT1 epitope binding antibodies in this new mouse model.  
Our results confirm a relative increase in AT1 epitope antibody binding activity from 
nulligravid to HOP and furthermore to PE samples.  Additionally, LIGHT-injected 
pregnant and non-pregnant mouse samples exhibited increased AT1 epitope binding 
activity. 
B. Materials and Methods        
191
 117
 scaffold.90   Samples from women who had never been pregnant (nulligravid) (n=21) 
and pregnant and non-pregnant mice were provided from the University of Texas, 
Houston Medical School.  Mouse model development and experiments were 
con
d not 
expressing peptide.  Statistical analysis of Mann-Whitney U test and ANOVA with 
Tukey’s multiple comparisons test was conducted using Prism4 or Prism6      
ducted by collaborators at the University of Texas, Houston Medical School.  To 
evaluate binding to antibodies present in human plasma samples, antibody fractions 
were enriched through ammonium sulfate precipitations and labeled with biotin.  
Incubating antibody fractions (1 μM) with the bacterial displayed fragment followed 
by diluted (1:333) streptavidin-conjugated R-phycoerythrin (SA-PE) (Invitrogen) 
enabled binding analysis by flow cytometric fluorescence.  Binding of the nulligravid 
samples was compared to previously analyzed PE (n=45) and healthy-outcome 
pregnancy (HOP) (n=48) samples (Chapter 2).191  Binding to antibodies present in 
mouse model samples utilized unprocessed diluted plasma (1:100) in PBS.  After 
incubating AT1 epitope expressing bacteria with mouse plasma, labeling steps 
proceeded with reagents diluted in PBS with 0.1% BSA.  A biotin-conjugated mouse 
IgG specific secondary (1:200) (Vector Labs) was followed by incubation with SA-
PE to fluorescently tag the antibodies bound to the AT1 epitope, enabling analysis by 
flow cytometry.  All antibody binding activity was measured in duplicate and 
normalized by background activity with a negative control, eCPX scaffol
C. Results and Discussion 
Using the AT1 epitope assay to detect antibodies demonstrated that nulligravid 
(n=21) samples exhibited similar binding activity as background.  In comparison to 
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 previously evaluated PE (n=45) and HOP (n=48) samples (Chapter 2),191 antibody 
binding activity in nulligravid samples was significantly reduced (Figure 5-1).  This 
agrees with previous results using the second extracellular loop of the AT1 receptor in 
an ELISA.178  In comparison, the nulligravid binding activity observed with the EB15 
and GPR50 fragments appeared similar to HOP but significantly lower than the PE 
activity (Figure 3-10).  Our results indicate that healthy pregnancy is associated with 
increased AT1-AA production, while patients with PE experience further escalations 
in antibody production.  Previous studies have demonstrated increased levels of pro-
inflammatory cytokines and decreased anti-inflammtory cytokine (IL-10) in PE 
compared to control.190  While reduced compared to PE, the pregnant control samples 
exhibited increased inflammatory cytokines compared with non-pregnant samples.  
Thus, inflammation could lead to increased autoantibody production with further 
intensity in PE resulting in aberrant levels.      
p <0.0001
p <0.01
p <0.01
 
 
Evaluating antibody binding to the AT1 epitope in non-pregnant mouse samples 
revealed a dynamic increase in binding activity upon infusion of LIGHT for 14 days 
(n=8) compared to saline (n=7) (Figure 5-2).  In contrast, a five day infusion (n=8) 
Figure 5-1: Antibody binding to the AT1 epitope is significantly reduced in nulligravid (NG) 
samples.  Binding activity compared to previously analyzed PE and HOP.  p – values 
hitney U test  represent results from Mann-W
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 did not significantly differ from saline injection.  Interestingly, injecting a tissue 
transglutaminase (tTG) blocker (n=5), cystamine, prevented this signal of antibody 
production, indicating tTG involvement.  This builds upon previous observations 
indicating a role for tTG in PE pathology.225  PE patients exhibited increased levels 
of tTG while cystamine reduced antibody mediated hypertension and proteinuria in 
the adoptive transfer mouse model.  Furthermore, a mouse knockout of the pro-
inflammatory cytokine IL-6 (IL-6-/-) infused with LIGHT (n=3) did not exhibit 
enhanced binding activity, instead showing similar levels to saline injection.  
Similarly, a conditional knockdown of hypoxia-inducible factor 1 alpha, HIF-1a, in 
endothelial cells (HIF-1a v-cad cre) did not exhibit increased antibody production 
upon LIGHT infusion (n=6).  These results indicated that increased autoantibody 
production by LIGHT was mediated by IL-6 and HIF-1a.   
 
 
While non-pregnant mice experiencing a 14 day infusion exhibited increased AT1 
Figure 5-2: LIGHT affects plasma antibody binding activity to the bacterial displayed AT1
epitope in non-pregnant mice. p-values indicate results from Tukey’s multiple comparisons
test following ANOVA 
epitope binding activity, pregnant mice could not be subjected to the same level of 
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 LIGHT injection without pregnancy loss.  Instead, pregnant mice had been injected 
with LIGHT at gestational day 13.5 and 14.5 of pregnancy.  Despite this reduced 
injection rate, the mice treated with LIGHT (n=13) demonstrated increased AT1 
epitope binding activity compared to saline injections (n=8) (Figure 5-3).  This 
apparent antibody binding activity mediated by LIGHT injection indicates potential 
placental involvement to initiate a similar response as the 14 day infusion in non-
pregnant mice.  Similarly, treatment with cystamine (n=4) reduced the antibody 
binding activity observed, although this result was not statistically significant due to 
increased variance.  However, mice treated with HIF-1a siRNA (small interfering or 
silencing RNA) and LIGHT (n=4) exhibited significantly reduced AT1 epitope 
binding.  Thus, results from pregnant mice reflect similar AT1 antibody production 
responses to LIGHT as the non-pregnant mice despite reduced injection.  
p < 0.03
p < 0.03 p < 0.05
 
Figure 5-3: In a pregnant mouse model, LIGHT induces plasma antibody binding to the 
bacterial displayed AT1 epitope. p-values indicate Mann-Whitney U test results  
Our results demonstrate the utility of this AT1 epitope binding assay for the 
detection of AT1-AAs in various samples.  The significantly reduced antibody 
binding to nulligravid samples confirms an epitope specific change in antibody 
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 production previously shown with the full-length second extracellular loop.178  
Furthermore, we have shown increased antibody binding to the AT1 epitope in 
response to LIGHT in non-pregnant and pregnant mice that involves tTG, IL-6, and 
HIF-1a.  Despite reduced LIGHT injection compared to non-pregnant mice, the 
pregnant mice exhibited a similar pattern of increased antibody production in 
response to LIGHT, pointing towards placental involvement.  Overall, these mouse 
model results indicate a relationship between the inflammatory condition associated 
with PE and autoantibody production.    
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 6. Conclusions 
While various biomarkers have been proposed for pre-eclampsia (PE) diagnosis, 
few have demonstrated accuracies required for clinical utility.  In an effort to fill this 
need, we focused on the circulating antibody repertoire and characterized antibody 
specificities in PE (Chapter 2).  Here, bacterial displayed peptide library screening 
identified PE-specific antibody-detecting peptides.  Using differently labeled 
antibody fractions enriched from plasma samples of PE and healthy-outcome 
pregnancies (HOP), multi-parameter cell sorting isolated PE cross-reactive and 
specific peptides.  We also developed a peptide display-based assay sensitive enough 
to detect antibody binding to the angiotensin II type 1 receptor (AT1) epitope without 
using complex biologic function based assays.2,138 This enables higher-throughput 
evaluation of AT1-AA activity, which was utilized to perform AT1 epitope specific 
analysis of antibodies present in a mouse model of PE (Chapter 5).   Furthermore, 
depleting antibodies binding this AT1 epitope verified that library screening identified 
antibody biomarkers present in PE patients distinct from known AT1-AAs.  A panel 
of antibody-detecting peptides, representing different antibody specificities, achieved 
strong diagnostic accuracy (80%) with high specificity (95%) in a set of cross-
validated training samples.  Importantly, we verified the 80% overall diagnostic 
accuracy from training in a full validation set of new samples, which differs from 
previous studies in the lab using machine learning algorithms.153,160  This represents 
A. Perspectives 
i. Developing an antibody-detecting diagnostic for pre-eclampsia 
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 an important step because many classification algorithms over-fit the training data.  
Combining the peptide panel with traditional diagnostic criteria of proteinuria and 
ulted in improved detection of PE patients that experienced severe 
sym e reactivity 
negatively correlated with platelet levels in PE patients, indicating a relationship 
between antibody binding and PE symptoms.  This study provided evidence for an 
altered antibody response in PE that resulted in the development of an antibody-
detecting peptide array to differentiate PE from HOP.  However, the characterized 
motifs did not enable unambiguous discovery of autoantigen or potential 
environmental trigger antigen.    
hypertension res
ptoms or delivered early (<37 weeks’ gestation).  Furthermore, peptid
ii. Identifying disease-associated antibody binding targets 
While discovery of disease-associated antibodies enabled development of a PE 
classifier, the identity of the corresponding antigen(s) could improve understanding 
of the antibody’s role in PE and elucidate potential therapeutic targets.  Furthermore, 
rather than the mimicking library peptides, utilizing whole or partial antigen(s) to 
detect antibody presence may enhance diagnostic accuracy of the assay.  Instead of 
antibody fractions, unprocessed, diluted plasma may better replicate the native 
antibody binding environment leading to improved motifs that more closely relate to 
protein targets.  Therefore, a second study screened against unprocessed plasma to 
discover a PE-associated binding motif using a significantly altered screening method 
and characterized antibody binding targets (Chapter 3).  Importantly, our results 
demonstrate a novel case for molecular mimicry operating near the time of delivery 
by which a PE-associated IgG1 antibody cross-reacts with a viral antigen (EBNA-1) 
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 and a human G protein-coupled receptor (GPR50).  While not a new concept, 
discovery of novel molecular mimicry mechanisms without depending on prior 
knowledge of disease pathology remains difficult.  Moreover, this marks our first 
successful venture to link a library peptide motif to previously uncharacterized 
antibody binding protein targets using bacterial display.  In characterizing this 
molecular mimicry interaction, we provided additional evidence suggesting that 
directed evolution of disease-associated motifs improves immune activity profiling, 
as previously shown in a celiac disease study.189  Through directed evolution, PE-
associated peptide binding activity increased and the correlation improved between 
library peptide reactivity and the ELISA signal observed for antibody binding to the 
identified target antigen, EBNA-1.  The EBNA-1 derived fragment (EB15) 
sequestered antibody binding activity to the GPR50 fragment and the full-length 
protein expressed in cells.  Furthermore, results indicated GPR50 expression in a 
trophoblast model cell line and placental tissue.  As an IgG1 subtype, this antibody 
can activate the complement system; therefore, antibody binding to this placental 
protein may contribute to the increased complement deposition observed.   
While additional findings, such as inhibition of the melatonin receptor 1,  may link 
GPR50 to PE-related disturbances, it remains unclear if aberrant antibody binding to 
this placental protein or other similar proteins causes any PE-related effects.  
However, since the EB15 peptide inhibited antibody binding to GPR50 in vitro, it 
might effectively block any aberrant antibody binding in vivo as well.  An adoptive 
transfer model, similar to the study on AT1-AAs in pregnant mice,  could provide 
119,122,173
198
3
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 insights into these questions of PE pathology and effective blocking activity for this 
GPR50 and EBNA-1 cross-reactive antibody.    
iii. Applying next-generation sequencing to profile individual antibody repertoires 
highlights alterations in PE 
In addition to the EBNA-1 linked specificity (Chapter 3) we sought to identify 
new motifs by characterizing individual antibody repertoires of PE and HOP 
(Chapter 4).  Using next-generation sequencing (NGS) enables higher resolution of 
individuals’ antibody specificities that can be cross-examined between healthy and 
disease samples.  Therefore, we developed and applied a unique methodology to 
profile individual patients’ antibody-binding repertoire using NGS to analyze 
sequences obtained from bacterial displayed library screening with PE and HOP 
samples (n=4, each).  Distinct individuals’ peptide encoding DNA sequences were 
isolated, PCR amplified, and uniquely barcoded to enable pooling.  After NGS, a 
computational algorithm (IMUNE) developed in the Daugherty Group at UCSB 
identified peptide patterns enriched separately in PE and HOP by cross-examining the 
individual repertoires.  Analysis of algorithm-derived patterns led to PE- and HOP-
associated motifs, which were confirmed using a second method of evaluating 
enriched sequences from different rounds of screening.  Thus, multiple approaches 
revealed similar alterations to the antibody repertoire.  Importantly, the previously 
characterized viral antigen (EBNA-1)-linked motif (KXXXC[VLI]GCK) was 
identified by this new method.  Re-identifying this motif validates the algorithm’s 
ability to discover disease-associated motifs and further demonstrates the motif’s 
reproducibility using various methods.  Another highly represented PE motif 
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 (L[YW]XWDXR) shared similarities with a number of human proteins.  
Interestingly, a third PE-associated motif shared strong similarities to the 
immunodominant region of EBNA-1,217 providing support for increased antibody 
binding activity against this viral antigen in PE.  Only one of the HOP-associated 
motifs yielded a reasonable number of hits (<20) for antigen fragment analysis; 
however, in general, these HOP-associated motifs shared similarities with a number 
of human pathogens.  The new motifs identified by this approach would benefit from 
directed evolution to characterize the candidate antigens they represent.  In general, 
this NGS-enabled in-depth motif analysis by cross-examination and peptide 
enrichment provides further evidence of a skewed antibody response in PE patients 
compared to HOP.   
iv. Overall conclusions 
Taken together, the results from these studies demonstrate changes in the 
circulating antibody repertoire in patients with PE compared to HOP.  These 
alterations enabled development of an antibody-detecting peptide-based classifier, 
achieving a validated accuracy of 80% for this heterogeneous disease.  Moreover, 
motif characterization through three methodologies revealed a skewed antibody 
response, resulting in PE- and HOP-associated binding motifs.  Thus, we have 
provided supporting evidence for an altered immune response in PE.  Several 
observations point to an aberrant immune response, including dysregulated 
complement system,118,119,122,173 altered levels of B-cells126 and T-cells,123,124 and an 
intensified inflammatory condition.190  Interestingly, the AT1-AA detection results 
from the LIGHT injected mouse model of PE provide a link between the increased 
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 inflammatory condition and antibody production.  As researchers continue to 
investigate the immunological alterations in PE, these different components, 
including aberrant autoantibody binding activity, may reveal insights into PE 
etiology.   
A significant contribution of this work is the demonstration of unbiased antibody 
binding target identification.  Specifically, library screening, directed evolution, and 
candidate antigen fragment activity analysis resulted in the characterization of a new 
example of molecular mimicry leading to antibody binding to human proteins.  While 
previous antigen discovery efforts were aided by pre-existing knowledge of disease 
etiology,189 our results emphasize the utility of peptide library screening for de novo 
identification of antigenic targets. Here, we applied this process to a PE-associated 
antibody specificity; however, this can be extended to a variety of diseases.  
Furthermore, we have demonstrated the powerful depth of sequence coverage 
provided by NGS, which will be an important tool for future applications of antibody 
repertoire profiling.  Combining individual repertoire profiling by NGS with directed 
evolution strategies will enable investigation of multiple disease-associated motifs in 
parallel, revealing broad insights into disease etiology.        
B.  Future Directions 
A major impact of these discoveries involves the new investigation opportunities 
they enable.  Our results indicate a molecular mimicry mechanism acting in PE near 
the time of delivery in which an antibody cross-reacts with the viral antigen EBNA-1 
and human protein GPR50.  Since mice also express GPR50 in the placenta,192 an 
adoptive transfer model, similar to the AT1-AAs investigation by our collaborators,3 
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 can investigate how this antibody activity might play a role in pathology.  To focus on 
this antibody specificity, GPR50/EBNA-1 binding antibodies could be purified from 
PE patients.  Purified antibody would be injected into pregnant mice with or without 
the blocking peptide EB15.  The minimum concentration of peptide required to fully 
blo
eady associated with PE.  
Therefore, extending the insights gained from our results into an in vivo mouse model 
could provide evidence of a pathological role for this newly identified PE-associated 
antibody specificity.   
In addition to this viral antigen-linked antibody specificity, NGS analysis of 
individual antibody repertoires identified PE and HOP-associated motifs.  However, 
these motifs often yielded a large number of hits from BLASTp or ScanProsite 
ck antibody binding to the GPR50 fragment was ~4x10-10 M, which means the 
antibody binding sites were largely saturated at this point.  Based on a bivalent 
antibody and the 1:200 plasma dilution performed for this assay, this yields roughly 
4x10-8 M of antibody in circulation.  Since we don’t know the precise affinity of the 
antibody for GPR50 or EB15, this serves as a rough estimate of the antibody 
concentration.  Based on a mouse blood volume of 2 mL, ~12.5 µg of purified 
antibody should be injected to obtain a comparable concentration.  In comparison, the 
AT1-AA adoptive transfer model injected ~20 µg of purified antibodies into pregnant 
mice.3  Taking several measurements, including blood pressure, urinary protein, and 
levels of melatonin, sFlt-1, and PlGF, will determine potential antibody effects and 
whether EB15 administration attenuates these effects.  Furthermore, evaluating the 
kidney or placenta for complement deposition173 might demonstrate this antibody’s 
role in the complement system dysregulation118-122,173 alr
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 searches.  Building upon previous success with directed evolution (Chapter 3),189 
these motifs can be further evolved to expand the epitope while increasing cross-
reactivity and specificity.  Applying this directed evolution strategy to the PE-
associated motif L[YW]XWDXR may enable identification of new PE-related 
antibody binding targets.  Especially interesting would be the discovery of an 
antibody specificity that is significantly reduced or lacking in PE patients.  A similar 
condition has been shown in children with recurrent infections that exhibit normal 
levels of total IgG but reduced activity towards Haemophilus influenzae type b, 
despite immunization.226  Combining measurements of differential antibody binding 
activities (reduced and enhanced) may improve diagnostic accuracy of an antibody-
detecting peptide panel.  For example, a profile of 19 increased/decreased serum-
derived peptides yielded a classifier with 93% and 90% accuracy in training and 
validation sets, respectively.205  Evolving these motifs will enable discovery of 
additional PE-associated alterations in antibody activity towards specific antigens.  
Characterizing these specificities could improve understanding of disease etiology 
and diagnostic performance of an antibody-detecting panel.  
Although we have demonstrated the benefit of a diagnostic tool near the time of 
delivery to detect PE, especially those with non-traditional PE presentation (i.e., no 
proteinuria), a predictive test is highly sought after.   Recently, 47 biomarkers were 
evaluated for PE identification during the first trimester with a large cohort of 5623 
pregnant women.146  However, the study showed that molecular biomarkers did not 
significantly improve predictive performance compared to clinical risk factors alone 
for all PE.  Combining the ratio of cystatin C/PlGF with clinical risk factors resulted 
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 in moderate predictive accuracy for early-onset PE in the validation set with 44% 
sensitivity at 95% specificity (AUC=0.73).  The low prevalence of early-onset PE 
(0.5% in the study) limits this model’s clinical application because for every one 
correctly diagnosed early PE there would be 23 false-positives.146  Thus, accurate 
prediction of PE during the first trimester remains elusive.  In an effort to fill this 
unmet need, samples obtained during the first trimester from women destined for PE 
and HOP can be screened for antibody markers.  After dividing the samples into 
discovery and validation sets, the discovery samples will be screened by individual 
antibody repertoire analysis with NGS followed by motif evolution.  Reactivity 
analysis with library peptides and antigen fragments in the validation set will provide 
preliminary performance statistics.  Given the overall success of our bacterial 
displayed library screening in PE near delivery191 and celiac disease,153,160,189 we 
hypothesize that first trimester screening of PE and HOP samples will yield predictive 
antibody biomarkers for PE detection.        
In addition to these PE-related future studies, different methodological advances, 
such as discontinuous or structural epitope discovery, remain unexplored.  Our 
studies on antibody epitope profiling have primarily focused on identifying linear 
epitopes or potentially, a linear section of a discontinuous epitope.  A substantial 
portion of all antibody epitopes are rather discontinuous, comprising residues from 
sections of greater than 40 amino acids.227  In fact, some estimate that peptides of 7-
15 amino acids in length from linear sections of candidate antigens recover all major 
functional residues only ~50% of the time.  Although it may not be important to 
capture all functional residues to retain activity, an understanding of the complete 
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 epitope may be desired.  Other studies have utilized pre-existing knowledge of 
discontinuous epitopes to refine the residues involved from discontiguous protein 
sections through co-incubation73 or fusion.66  However, the biterminal eCPX scaffold 
enables conveniently linked co-expression of different peptides.  Therefore, an 
identified disease-related motif or specific peptide can be expressed on one terminus 
with a peptide library expressed on the other.  Screening for cooperatively enhanced 
binding may reveal additional functional residues stemming from a discontinuous 
section.  Identifying important functional residues of a discontinuous epitope may 
help boost antibody detection sensitivity.  Moreover, in combination with 
discontinuous epitope prediction tools167 different candidate targets can be 
investigated for alignment with these discontinuous motifs.  In addition to probing for 
linear sections of discontinuous epitopes, we can search for structural mimotopes with 
different library constructions.  As previously discussed, a library designed to include 
multiple disulfide constraints affected the apparent affinity of identified antibody 
binders (Chapter 1).  We hypothesized that the structure imparted by these disulfide 
bonds enables selection of high affinity structural mimotopes.  While these might be 
difficult to relate to an antigenic target, the efficacy of these peptides as diagnostic 
reagents has not been investigated.  For direct comparison, the same patients used for 
screening in the ADEPt189 method (Chapter 3) that yielded the EBNA-1/GPR50 
motif can be screened against this multiply-constrained peptide library.  Since 
screening the fully randomized library naturally identified a disulfide-constrained 
motif, it will be interesting to compare the motif results from screening a library that 
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 already includes such constraints.  These different library construction approaches 
could yield novel discontinuous and structural epitopes/mimotopes.            
While applying NGS to isolated peptides from library screening profiles the 
binding repertoire, this high-throughput technology has also provided insights into the 
antibody sequences themselves.  Specifically, sorting and sequencing individual 
antibody producing plasmablasts provides a profile of the current immune response.  
This group of cells typically represents a small percentage (<1%) of circulating B-
cells.  However, recent exposures (e.g., infection) or chronic immune responses (e.g., 
autoimmune diseases) increase the presence of these plasmablasts (>30% in 
infections).213  Methodological advances have enabled sequencing of the entire 
variable region of the antibodies produced by these plasmablasts.51,52,213  Combining 
these variable regions with constant domains facilitates production of human derived 
full-length antibodies in the lab.  However, the binding specificities of these 
antibodies must then be determined.  Thus far, studies of plasmablast-derived 
antibodies have relied upon pre-existing knowledge to probe protein microarrays.  
However, our technology represents an invaluable tool for profiling antibody binding 
specificities.  Specifically, by screening bacterial displayed peptide libraries against 
these human-derived antibodies, their individual binding specificities can be 
characterized.  As previously demonstrated, searching the identified binding motifs in 
protein databases yields candidate antigens.  While these candidate hits can be 
evaluated individually by bacterial displayed fragment analysis, protein/peptide 
microarrays based on these unbiased search results can also be constructed and 
probed.  Therefore, combining NGS-based antibody sequencing with bacterial 
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 displayed peptide library antibody profiling will provide a direct link between the 
antibody species and the specific epitope to which it binds.   
Through this work, we have established the powerful utility of bacterial displayed 
peptide library screening to profile the antibody repertoire.  The results from this 
work demonstrate this tool’s application for diagnostic development and the ability to 
gain insights into disease etiology through antibody target identification.  Thus, this 
impactful technology provides new ways to expand our knowledge of the changes to 
the circulating antibody repertoire in response to disease.   
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